Marina Konopleva

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/3a462040-725e-11ed-bf6e-5b21ae3cc73b.jpg

First Name

Marina

Last Name

Konopleva

NPI

1518063486

Faculty ID

17308

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p class="MsoNormal">My laboratory and clinical research are focusing on novel agents in acute myeloid leukemia. The main area of active investigations is attacking apoptotic machinery of leukemia cells by depriving them from key pro-survival inputs by targeting BCL-2, BCL-XL, Mcl-1 by small molecule inhibitors and degraders. We continue studies characterizing mechanisms of resistance to BCL-2 inhibition and identifying novel combinatorial strategies with immune therapies and signaling inhibitors. My lab is interested in studying the biology and therapeutic targeting of leukemia-initiating cells, with novel multi-targeted bispecific T- or NK-engagers, antibody-drug conjugates and CART cells. We further aim at identifying key targets in maintenance and eradication of minimal residual disease (MRD) in acute myeloid leukemia (AML). We have studied metabolic states in AML and T-ALL and utilized novel metabolic inhibitors to selectively deprive tumor metabolism, such as glutaminase, OxPhos and fatty acid metabolic inhibitors. Finally, we are interested in understanding the biology and targeting of an aggressive hematologic malignancy Blastic Plasmacytoid Dendritic ell neoplasm (BPDCN), through targeting BCL-2, CD123 and novel cell surface targets with small molecules, antibodies and CART cells. Most robust pre-clinical discoveries have translated into clinical trials, such as venetoclax, metabolic inhibitors and immune modulators.</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Myelodysplastic Syndrome (MDS)&nbsp;<br />

Elsevier Profile

Selected Publications

<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;">Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, Cortes J, DeAngelo DJ, Debose L, Mu H, D&ouml;hner H, Gaidzik VI, Galinsky I, Golfman LS, Haferlach T, Harutyunyan KG, Hu J, Leverson JD, Marcucci G, M&uuml;schen M, Newman R, Park E, Ruvolo PP, Ruvolo V, Ryan J, Schindela S, Zweidler-McKay P, Stone RM, Kantarjian H, Andreeff M, Konopleva M, Letai AG (co-corresponding last author). Selective BCL-2 Inhibition by ABT-199 Causes On Target Cell Death in Acute Myeloid Leukemia. Cancer Discov 4(3):362-75, 3/2014. e-Pub 12/2013. PMCID: PMC3975047.</p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;">Zhang Q, Riley-Gillis B, Han L, Jia Y, Lodi A, Zhang H, Ganesan S, Pan R, Konoplev SN, Sweeney SR, Ryan JA, Jitkova Y, Dunner K, Grosskurth SE, Vijay P, Ghosh S, Lu C, Ma W, Kurtz S, Ruvolo VR, Ma H, Weng CC, Ramage CL, Baran N, Shi C, Cai T, Davis RE, Battula VL, Mi Y, Wang J, DiNardo CD, Andreeff M, Tyner JW, Schimmer A, Letai A, Padua RA, Bueso-Ramos CE, Tiziani S, Leverson J, Popovic R, Konopleva M. Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduct Target Ther 7(1):51, 2/2022. e-Pub 2/2022. PMID: 35185150.</p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;">&nbsp;</p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;">DiNardo CD, Konopleva MY. A venetoclax bench-to-bedside story. Nat Cancer 2(1):3-5, 1/2021. PMID: 35121895.</p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;">&nbsp;</p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;">Baran N, Lodi A, Dhungana Y,&nbsp; Herbrich S,&nbsp; Collins M, Sweeney S,&nbsp; Pandey R, Skwarska A,&nbsp; Patel S,&nbsp; Tremblay M,&nbsp; Kuruvilla VM,&nbsp; Cavazos A,&nbsp; Kaplan&nbsp; M,&nbsp; Warmoes MO,&nbsp; Veiga DT,&nbsp; Furudate K,&nbsp; Rojas-Sutterin S, Haman A,&nbsp; Gareau Y,&nbsp; Marinier A, Ma H,&nbsp; Harutyunyan K,&nbsp; Daher M,&nbsp; Garcia LM,&nbsp; Al-Atrash G,&nbsp; Piya S, Ruvolo V, Yang W,&nbsp; Shanmugavelandy SS,&nbsp; Feng N,&nbsp; Gay J,&nbsp; Du D,&nbsp; Yang JJ,&nbsp; Hoff FW,&nbsp; Kaminski M,&nbsp; Tomczak K, Davis&nbsp; RE, Herranz D,&nbsp; Ferrando A,&nbsp; Jabbour EJ, Di Francesco ME,&nbsp; Teachey DT,&nbsp; Horton TM,&nbsp; Kornblau S, Rezvani K, Sauvageau G,&nbsp; Gagea M, Andreeff M, Takahashi K,&nbsp; Marszalek JR,&nbsp; Lorenzi PL, Yu J, Tiziani S, Hoang T, Konopleva M. Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia. Nat Commun. 13(1):2801, 5/2022. PMID:35589701.</p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;">&nbsp;</p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;">Cai T, Gouble A, Black KL, Skwarska A, Naqvi AS, Taylor D, Zhao M, Yuan Q, Sugita M, Zhang Q, Galetto R, Filipe S, Cavazos A, Han L, Kuruvilla V, Ma H, Weng C, Liu CG, Liu X, Konoplev S, Gu J, Tang G, Su X, Al-Atrash G, Ciurea S, Neelapu SS, Lane AA, Kantarjian H, Guzman ML, Pemmaraju N, Smith J, Thomas-Tikhonenko A, Konopleva M. Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells. Nat Commun 13(1):2228, 4/2022. PMCID: PMC9051102.</p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;">&nbsp;</p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;">Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M. Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. N Engl J Med 380(17):1628-1637, 4/2019. PMID: 31018069.</p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;">&nbsp;</p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;">Herbrich S, Baran N, Cai T, Weng C, Aitken MJL, Post SM, Henderson J, Shi C, Richard-Carpentier G, Sauvageau G, Baggerly K, Al-Atrash G, Davis RE, Daver N, Zha D, Konopleva M. Overexpression of CD200 is a Stem Cell-Specific Mechanism of Immune Evasion in AML. J Immunother Cancer 9(7):e002968, 7/2021. PMID: 34326171.</p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;">&nbsp;</p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;">Yap TA, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, Kantarjian HM, Ravandi F, Collins ME, Francesco MED, Dumbrava EE, Fu S, Gao S, Gay JP, Gera S, Han J, Hong DS, Jabbour EJ, Ju Z, Karp DD, Lodi A, Molina JR, Baran N, Naing A, Ohanian M, Pant S, Pemmaraju N, Bose P, Piha-Paul SA, Rodon J, Salguero C, Sasaki K, Singh AK, Subbiah V, Tsimberidou AM, Xu QA, Yilmaz M, Zhang Q, Li Y, Bristow CA, Bhattacharjee MB, Tiziani S, Heffernan TP, Vellano CP, Jones P, Heijnen CJ, Kavelaars A, Marszalek JR, Konopleva M. (2023). Complex I Inhibitor of Oxidative Phosphorylation in Advanced Solid Tumors and Acute Myeloid Leukemia: Phase I Trials. Nat Med. 29(1), 115-126. PMID: 36658425</p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;">&nbsp;</p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;">Jia Y, Han L, Ramage CL, Wang Z, Weng CC, Yang L, Colla S, Ma H, Zhang W, Andreeff M, Daver N, Jain N, Pemmaraju N, Bhalla K, Mustjoki S, Zhang P, Zheng G, Zhou D, Zhang Q, Konopleva M. (2023). Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells. Haematologica 2023 Apr 20 [<em>online ahead of print</em>]. PMID: 37078252</p>

EMR ID

177440

Biography

<p>Marina Konopleva, MD, Phd, is Professor, Oncology, Professor, Molecular Pharmacology, Director, Leukemia Program and Co-Director, Blood Cancer Institute, at Montefiore Einstein. Her clinic focus centers on treating patients with hematologic malignancies, with an emphasis on acute myeloid and acute lymphoblastic leukemia. She has additional expertise in treating patients with high-risk myelodysplastic syndrome and chronic myeloid leukemia.</p><p>After obtaining her Doctor of Medicine in 1990 from First Pavlov Medical Institute in St. Petersburg, Russia, Dr. Konopleva completed her postgraduate training in internal medicine at I.P. Pavlov State Medical Institute in 1993. In 1998 she obtained her PhD in experimental hematology from the Federal Institute of Hematology and Blood Transfusion as well as her postdoctoral fellowship in Molecular Hematology with The University of Texas MD Anderson Cancer Center.</p><p>Dr. Konopleva conducts laboratory research focusing on approaches activating cell death, metabolic inhibitors and immune-oncology in AML. Her key contributions include the identification of dependency of AML cells on the anti-apoptotic protein BCL-2 and the FDA approval of the BCL-2 inhibitor venetoclax in combination with low-intensity chemotherapy in elderly patients unfit for standard chemotherapy. This therapy provides both low toxicity for elderly patients with AML and documented survival benefit. Dr. Konopleva&rsquo;s ground-breaking research greatly benefited leukemia research, clinical research and the lives of patients. She is a scholar of the Leukemia and Lymphoma Society and her research is funded by the NIH, Department of Defense and various private foundations. Her work has been published in numerous peer-reviewed journals and she has presented both nationally and internationally.</p><p>Dr. Konopleva is board certified by the Russian Board of Hematology, the American Board of Internal Medicine and the American Board of Internal Medicine - Hematology. She is a member of numerous professional societies including the American Society of Hematology, the American Association of Cancer Research, the American Society of Clinical Oncology, the American Society for Clinical Investigation and the Society of Hematologic Oncology.</p><p>Dr. Konopleva has won many awards for her work, such as the R. Lee Clark Prize - Basic/Translational Science and the Students' Faculty Choice Award from MD Anderson Cancer Center in 2019, the Otis W. and Pearl L. Walters Faculty Achievement Award in Clinical Research from MD Anderson Cancer Center in 2020 and the Mentor of the Year award from the Division of Cancer Medicine, MD Anderson Cancer Center in 2022.</p>

Is Open Scheduling

Off

Johnny Yap

https://assets.montefioreeinstein.org/profiles/images/physphoto/Yap_Johnny_MD_420x504-2.jpg

First Name

Johnny

Last Name

Yap

NPI

1790766269

Faculty ID

17426

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Utilizing a broad range of radiation treatment technologies.

Research Focus

Breast cancer.

Elsevier Profile

EMR ID

113299

Biography

<p>Johnny Yap, MD, is a Radiation Oncologist and Assistant Professor, Radiation Oncology at Montefiore Einstein. With a clinical focus is in breast, gastrointestinal, gynecological, lung and stereotactic radiation, Dr. Yap has expertise with utilizing a broad range of radiation treatment technologies.</p><p>After earning his Doctor of Medicine at Rosalind Franklin University, Chicago Medical School in 1995, Dr. Yap completed his internship at Yale University in 1996, followed by his radiation oncology residency at Wayne State University Medical Center, Detroit Medical Center in 2000.</p><p>Dr. Yap&rsquo;s research interests focus on breast cancer. His work has been shared in peer-reviewed journals as well as posters, abstracts and oral presentations. Dr. Yap is also an editorial board member and reviewer for <em>Journal of Gastrointestinal Oncology</em>.</p><p>Dr. Yap is board certified by the American Board of Radiology and is a member of the American Society of Radiation Oncology and the Radiosurgery Society.</p>

Is Open Scheduling

Off

Amit K. Verma

https://assets.montefioreeinstein.org/profiles/images/Verma_Amit_MD_2x.jpg

First Name

Amit

Last Name

Verma

NPI

1033299524

Faculty ID

10065

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>https://einsteinmed.edu/labs/amit-verma/</p&gt;
<p><strong style="text-align: justify;">Targeting signal transduction in hematologic malignancies</strong><span style="text-align: justify;">:&nbsp;<br /></span><span style="text-align: justify;">Cytokines play important roles in the regulation of normal hematopoiesis and a balance between the actions of hematopoietic growth factors and myelosuppressive factors is required for optimal production of different hematopoietic cell lineages. The myelodysplastic syndromes (MDS) are collections of heterogeneous hematologic diseases characterized by refractory cytopenias due to ineffective hematopoiesis. These preleukemic disorders are common causes of anemia in the elderly and are rapidly increasing in incidence. We have also demonstrated that the TGF-beta superfamily/smad, IRAK and MAP kinase pathways is overactivated in MDS. Our work has led to clinical trials with Luspatercept, Galunisertib, CA4948, ARRY-614 and various other promising agents in MDS. We are trying to study the molecular mechanisms that lead to the activation of these pathways in MDS and are using small molecule inhibitors in mouse models to target these pathways.&nbsp;</span></p>
<p style="text-align: justify;"><strong>Targeting aberrant stem and progenitor cells in myelodysplastic neoplasms:&nbsp;<br /></strong>We have demonstrated that aberrant stem cells persist during morphological remissions and are involved in relapse. We have identified novel targets against MDS/AML stem cells that are being tested in various studies. We are also conducting sequencing/epigenetic analysis of highly purified human stem cells and evaluating the role of these alterations in transformation of MDS to AML.&nbsp;</p>
<p style="text-align: justify;"><strong>Epigenomic analysis of tumors</strong>: <br />We are using high throughput assays to analyze DNA methylation across the genome and have optimized these assays to work with low amounts of DNA. We have successfully used these assays in conducting an integrative analysis of epigenetic and genetic alterations in various tumor models, including MDS, esophageal cancer, pancreatic cancer and renal cell cancer.</p>
<p style="text-align: justify;"><strong>Clinical studies in Myelodysplastic syndromes</strong>: <br />We have a &ldquo;center of excellence&rdquo; clinic for patients with Myelodysplatic syndromes. We offer a variety of clinical trials for these patients.</p>

Research Areas

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Verma is a blood cancer expert, who specializes in the research and treatment of blood cancers.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Verma conducts clinical studies for patients with MDS and leukemia and offers a variety of clinical trials for these patients.

Research Focus

Dr. Verma conducts laboratory research aimed at discovering new treatments for myelodysplastic syndromes (MDS) and leukemias, and his research has shown that the TGF-beta superfamily/smad, IRAK and MAP kinase pathways are overactivated in MDS. His work has led to clinical trials with Luspatercept, Galunisertib, CA4948, ARRY-614 and various other promising agents in MDS. DR. Verma’s research has shown that MDS and leukemias are caused by aberrant leukemic stem cells and has identified novel targets against MDS/AML stem cells that are being tested in various studies. 

Elsevier Profile

Lab Website Link

Selected Publications

<ol>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/40424086/&quot; target="_blank">Splicing of erythroid transcription factor is associated with therapeutic response in myelodysplastic syndromes.</a><br/>Aluri S, Ling T, Fraint E, Chakraborty S, Zhang K, Ahsan A, Kravets L, Poigaialwar G, Zhao R, Pradhan K, Cotton A, Bachiashvili K, Yang JI, Budhathoki A, Agarwal B, Gordon-Mitchell S, Carbajal M, Sahu S, Boultwood J, Pellagatti A, Steidl U, Wickrema A, Nandakumar S, Shastri A, Suragani RN, Bowman TV, Crispino JD, Vodala S, <strong>Verma A. J Clin Invest.</strong> 2025 May 27. PMID: 40424086.</li>

<li><a href="https://pubmed.ncbi.nlm.nih.gov/40333990/&quot; target="_blank">Splicing regulatory dynamics for precision analysis and treatment of heterogeneous leukemias.</a><br/>Venkatasubramanian M, Schwartz L, Ramachandra N, Bennett J, Subramanian KR, Chen X, Gordon-Mitchell S, Fromowitz A, Pradhan K, Shechter D, Sahu S, Heiser D, Scherle P, Chetal K, Kulkarni A, Lee D, Zhou J, Myers KC, Tseng E, Weirauch MT, Grimes HL,* Starczynowski DT,* <strong>Verma A</strong>,* Salomonis N.* <strong>Sci Transl Med</strong>. 2025 May 7. PMID: 40333990. *Co Corresponding</li>

<li> <a href="https://pubmed.ncbi.nlm.nih.gov/39316768/&quot; target="_blank">A Weekly Low-Dose Regimen of Decitabine and Venetoclax is Efficacious and Less Myelotoxic in a Racially Diverse Cohort.</a><br />
Goldfinger M, Mantzaris I, Shastri A, Saunthararajah Y, Gritsman K, Sica A, Kornblum N, Shah N, Levitz D, Rockwell B, Shapiro LC, Gupta R, Pradhan K, Xue X, Munoz A, Dhawan A, Fehn K, Comas M, Verceles JA, Jonas BA, Kambhampati S, Shi Y, Braunschweig I, Cooper DL, Konopleva MY, Feldman EJ, <strong>Verma A. <br />
<em>Blood</em></strong>. 2024 Sep 24.PMID: 39316768 </li>
<li> <a href="https://pubmed.ncbi.nlm.nih.gov/39300320/&quot; target="_blank">Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses.</a><br />
DiNardo CD, Verma D, Baran N, Bhagat TD, Skwarska A, Lodi A, Saxena K, Cai T, Su X, Guerra VA, Poigaialwar G, Kuruvilla VM, Konoplev S, Gordon-Mitchell S, Pradhan K, Aluri S, Hackman GL, Chaudhry S, Collins M, Sweeney SR, Busquets J, Rathore AS, Deng Q, Green MR, Grant S, Demo S, Choudhary GS, Sahu S, Agarwal B, Spodek M, Thiruthuvanathan V, Will B, Steidl U, Tippett GD, Burger J, Borthakur G, Jabbour E, Pemmaraju N, Kadia T, Kornblau S, Daver NG, Naqvi K, Short NJ, Garcia-Manero G, Tiziani S, <strong>Verma A*</strong>, Konopleva M*.<br />
<strong><em>Nat Cancer</em></strong>. 2024 Sep 19. PMID: 39300320 <br />
*CoCorresponding </li>
<li> <a href="https://pubmed.ncbi.nlm.nih.gov/39294495/&quot; target="_blank">Pharmacological restriction of genomic binding sites redirects PU.1 pioneer transcription factor activity.</a><br />
Taylor SJ, Stauber J, Bohorquez O, Tatsumi G, Kumari R, Chakraborty J, Bartholdy BA, Schwenger E, Sundaravel S, Farahat AA, Wheat JC, Goldfinger M, <strong>Verma A</strong>, Kumar A, Boykin DW, Stengel KR, Poon GMK, Steidl U.<br />
<strong><em>Nat Genet</em></strong>. 2024 Sep 18. PMID: 39294495 </li>
<li> <a href="https://pubmed.ncbi.nlm.nih.gov/38521065/&quot; target="_blank">Transcription elongation defects link oncogenic SF3B1 mutations to targetable alterations in chromatin landscape.</a><br />
Boddu PC, Gupta AK, Roy R, De La Peña Avalos B, Olazabal-Herrero A, Neuenkirchen N, Zimmer JT, Chandhok NS, King D, Nannya Y, Ogawa S, Lin H, Simon MD, Dray E, Kupfer GM, <strong>Verma A</strong>, Neugebauer KM, Pillai MM. <strong><em>Mol Cell</em></strong>. 2024 Apr 18;84(8):1475-1495.e18.PMID: 38521065 </li>
<li> Aminov S*, Giricz O*, Melnekoff DT*, Sica RA*, Polishchuk V, Papazoglu C, Yates B, Wang HW, Sahu S, Wang Y, Gordon-Mitchell S, Leshchenko VV, Schinke C, Pradhan K, Aluri S, Sohn M, Barta SK, Agarwal B, Goldfinger M, Mantzaris I, Shastri A, Matsui W, Steidl U, Brody JD, Shah NN^, Parekh S^, <strong>Verma A</strong>^ Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency <em><strong>JCI</strong></em>, 2024 Feb 20 PMID: 38376944 </li>
<li> Thakkar A, Pradhan K, Duva B, Carre&ntilde;o JM, Sahu S, Thiruthuvanathan V, Campbel S, Gallego S, Bhagat TD, Rivera J, Choudhary G, Olea R, Sabalza M, Shapiro LC, Lee M, Quinn R, Mantzaris I, Chu E, Will B, Pirofski LA, Krammer F, <strong>Verma A</strong>*, Halmos B*&nbsp; Study of efficacy and longevity of immune response to 3rd and 4th doses of COVID-19 vaccines in patients with cancer: a single arm clinical trial&nbsp; <em><strong>Elife</strong></em> 2023, Mar 28;12:e83694. PMID: 36975207 </li>
<li> Levitz D, Saunthararajah Y, Fedorov K, Shapiro LC, Mantzaris I, Shastri A, Kornblum N, Sica RA, Shah N, Konopleva M, Gritsman K, Braunschweig I, Cooper DL, Pradhan K, <strong>Verma A,</strong> Feldman EJ, Goldfinger M. A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML. <em><strong>Clin Cancer Res.</strong></em> 2023 Aug 1;29(15):2774-2780. PMID: 37341641. </li>
<li> Choudhary GS, Pellagatti A, Agianian B, Smith MA, Bhagat TD, Gordon-Mitchell S, Sahu S, Pandey S, Shah N, Aluri S, Aggarwal R, Aminov S, Schwartz L, Steeples V, Booher RN, Ramachandra M, Samson M, Carbajal M, Pradhan K, Bowman TV, Pillai MM, Will B, Wickrema A, Shastri A, Bradley RK, Martell RE, Steidl UG, Gavathiotis E, Boultwood J, Starczynowski DT*, <strong>Verma A</strong>*. Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations. <strong>Elife</strong></em>. 2022 Aug 30;11:e78136. PMID: 36040792; PMCID: PMC9427103. </li>
<li>Jasra S, Giricz O, Zeig-Owens R, Pradhan K, Goldfarb DG, Barreto-Galvez A, Silver AJ, Chen J, Sahu S, Gordon-Mitchell S, Choudhary GS, Aluri S, Bhagat TD, Shastri A, Bejan CA, Stockton SS, Spaulding TP, Thiruthuvanathan V, Goto H, Gerhardt J, Haider SH, Veerappan A, Bartenstein M, Nwankwo G, Landgren O, Weiden MD, Lekostaj J, Bender R, Fletcher F, Greenberger L, Ebert BL, Steidl U, Will B, Nolan A, Madireddy A, Savona MR, Prezant DJ, <strong>Verma A</strong>. High burden of clonal hematopoiesis in first responders exposed to the World Trade Center disaster. <strong><em>Nat Med</em></strong>. 2022 Mar 7. PMID: 35256801.</li>
<li>Lee M, Quinn R, Pradhan K, Fedorov K, Levitz D, Fromowitz A, Thakkar A, Shapiro LC, Kabarriti R, Ruiz RE, Andrews EM, Thota R, Chu E, Kalnicki S, Goldstein Y, Loeb D, Racine A, Halmos B, Mehta V, <strong>Verma A</strong>. Impact of COVID-19 on case fatality rate of patients with cancer during the Omicron wave. <strong><em>Cancer Cell.</em></strong> 2022 Feb 22: PMID: 35219358; PMCID: PMC8860706</li>
<li>Shapiro LC, Thakkar A, Campbell ST, Forest SK, Pradhan K, Gonzalez-Lugo JD, Quinn R, Bhagat TD, Choudhary GS, McCort M, Sica RA, Goldfinger M, Goel S, Anampa JD, Levitz D, Fromowitz A, Shah AP, Sklow C, Alfieri G, Racine A, Wolgast L, Greenberger L, <strong>Verma A</strong>*, Halmos B*. *Co-Corresponding Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer. <strong><em>Cancer Cell</em></strong>. 2022 Jan 10;40(1):3-5. PMID: 34838186; PMCID: PMC8595142.</li>
<li>Komrokji RS, Platzbecker U, Fenaux P, Zeidan AM, Garcia-Manero G, Mufti GJ, Santini V, D&iacute;ez-Campelo M, Finelli C, Jurcic JG, Greenberg PL, Sekeres MA, DeZern AE, Savona MR, Shetty JK, Ito R, Zhang G, Ha X, Backstrom JT, <strong>Verma A</strong>. Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. <strong><em>Leukemia.</em></strong> 2022 Feb 26. PMID: 35220402.</li>
<li>Pinho S, Wei Q, Maryanovich M, Zhang D, Balandr&aacute;n JC, Pierce H, Nakahara F, Di Staulo A, Bartholdy BA, Xu J, Borger DK,<strong> Verma A</strong>, Frenette PS. VCAM1 confers innate immune tolerance on haematopoietic and leukaemic stem cells. <strong><em>Nat Cell Biol</em></strong>. 2022 Feb 24. PMID: 35210567.</li>
<li>Myer PA, Lee JK, Madison RW, Pradhan K, Newberg JY, Isasi CR, Klempner SJ, Frampton GM, Ross JS, Venstrom JM, Schrock AB, Das S, Augenlicht L, <strong>Verma A</strong>, Greally JM, Raj SM, Goel S, Ali SM. The Genomics of Colorectal Cancer in Populations with African and European Ancestry. <strong><em>Cancer Discov.</em></strong> 2022 Feb 17: PMID: 35176763.</li>
<li>Su H, Jiang M, Senevirathne C, Aluri S, Zhang T, Guo H, Xavier-Ferrucio J, Jin S, Tran NT, Liu SM, Sun CW, Zhu Y, Zhao Q, Chen Y, Cable L, Shen Y, Liu J, Qu CK, Han X, Klug CA, Bhatia R, Chen Y, Nimer SD, Zheng YG, Iancu-Rubin C, Jin J, Deng H, Krause DS, Xiang J, <strong>Verma A*</strong>, Luo M*, Zhao X*. Methylation of dual-specificity phosphatase 4 controls cell differentiation. <em><strong>Cell Rep.</strong></em> 2021 Jul 27;36(4):109421. PMID: 34320342. *Co-Corresponding.</li>
<li>Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, Rahman S, Kim SY, Ko B, Sica RA, Kornblum N, Bachier-Rodriguez L, McCort M, Goel S, Perez-Soler R, Packer S, Sparano J, Gartrell B, Makower D, Goldstein YD, Wolgast L, <strong>Verma A*</strong>, Halmos B*. Seroconversion rates following COVID-19 vaccination among patients with cancer. <em><strong>Cancer Cell</strong></em>. 2021 Jun 5: PMID: 34133951; PMCID: PMC8179248. *Co-Corresponding</li>
<li>Ueda K, Kumari R, Schwenger E, Wheat JC, Bohorquez O, Narayanagari SR, Taylor SJ, Carvajal LA, Pradhan K, Bartholdy B, Todorova TI, Goto H, Sun D, Chen J, Shan J, Song Y, Montagna C, Pellagatti A, Boultwood J, Xiong S, Lozano G, <strong>Verma A</strong>, Steidl U. MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism. <em><strong>Cancer Cell</strong></em>. 2021 Apr 12;39(4):529-547.e7. PMID: 33667384.</li>
<li>Weinreb JT, Ghazale N, Pradhan K, Gupta V, Potts KS, Tricomi B, Daniels NJ, Padgett RA, Oliveira SD, <strong>Verma A</strong>, Bowman TV Excessive R-loops Trigger an Inflammatory Cascade Leading to Increased HSPC Production <em><strong>Dev Cell</strong></em>, 2021, Mar 8;56(5):627-640. PMID: 33651979.</li>
<li>Shapiro LC, Mustafa J, Lombardo A, Khatun F, Joseph F, Gillick K, Naik A, Elkind R, Abreu M, Fehn K, de Castro A, Pradhan K, Binakaj D, Nelson R, Paroder M, Uehlinger J, Gritsman K, Alejandro Sica R, Kornblum N, Shastri A, Mantzaris I, Bachier-Rodriguez L, <strong>Verma A</strong>, Braunschweig I, Goldfinger M. Safety of axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma in an elderly intercity population. <em><strong>Bone Marrow Transplant</strong></em>. 2021 Jul;56(7):1761-1763. PMID: 33846558.</li>
<li>Thakkar A, Pradhan K, Jindal S, Cui Z, Rockwell B, Shah AP, Packer S, Sica RA, Sparano J, Goldstein DY, <strong>Verma A</strong>, Goel S, Halmos B Patterns of seroconversion for SARS-CoV2-IgG in patients with malignant disease and association with anti-cancer therapy <em><strong>Nature Cancer</strong></em>, 2021, 2: 392&ndash;399.</li>
<li>Mehta V*, Goel S*, Kabarriti R*, Cole D, Goldfinger M, Acuna-Villaorduna A, Pradhan K, Thota R, Reissman S, Sparano JA, Gartrell BA, Smith RV, Ohri N, Garg M, Racine AD, Kalnicki S, Perez-Soler R, Halmos B*, <strong>Verma A*</strong>. Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. <em><strong>Cancer Discov</strong></em>. 2020 Jul;10(7):935-941. PMID: 32357994; PMCID: PMC7334098.</li>
<li>List AF, Sun Z, <strong>Verma A*</strong>, Bennett JM, Komrokji RS, McGraw K, Maciejewski J, Altman J, Cheema PS, Claxton DF, Luger SM, Mattison RJ, Wassenaar T, Artz AA, Schiffer CA, Litzow MR, Tallman MS Lenalidomide-Epoetin Alfa versus Lenalidomide-monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin <em><strong>JCO</strong></em>, 2021, Jan 13: PMID: 33439748 *Corresponding.</li>
<li>COVID-19 and Cancer Consortium. A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. <em><strong>Cancer Cell</strong></em>. 2020 Dec 14;38(6):761-766. PMID: 33176160; PMCID: PMC7598547.</li>
<li>Kuderer NM, Choueiri TK, et al. Mishra S, Lyman GH, Rini BI, Warner JL; COVID-19 and Cancer Consortium. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <em><strong>Lancet</strong></em>. 2020 Jun 20;395(10241):1907-1918. PMID: 32473681; PMCID: PMC7255743.</li>
<li><strong>Verma A</strong>, Suragani RN, Aluri S, Shah N, Bhagat TD, Alexander MJ, Komrokji R, Kumar R. Biological basis for efficacy of activing receptor ligand traps in myelodysplastic syndromes. <strong>J Clin Invest.</strong> 2020 Feb 3;130(2):582-589. doi: 10.1172/JCI133678. Review. PMID: 31961337</li>
<li>Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, D&iacute;ez-Campelo M, Finelli C, Cazzola M, Ilhan O, Sekeres MA, Falantes JF, Arrizabalaga B, Salvi F, Giai V, Vyas P, Bowen D, Selleslag D, DeZern AE, Jurcic JG, Germing U, G&ouml;tze KS, Quesnel B, Beyne-Rauzy O, Cluzeau T, Voso MT, Mazure D, Vellenga E, Greenberg PL, Hellstr&ouml;m-Lindberg E, Zeidan AM, Ad&egrave;s L, <strong>Verma A</strong>, Savona MR, Laadem A, Benzohra A, Zhang J, Rampersad A, Dunshee DR, Linde PG, Sherman ML, Komrokji RS, List AF. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. <strong>N Engl J Med.</strong> 2020 Jan 9;382(2):140-151. PMID: 31914241</li>
<li>Bhagat TD, Ahrens DV, Dawlaty M, Zou Y, Baddour J, Achreja A, Zhao H, Yang L, Patel N, Kwak C,&nbsp; Choudhary G, Gordon-Mitchell S, Alluri S, Bhattacharyya S, Yu Y, Bartenstein M, Giricz O, Suzuki M, Sohal D, Gupta S, Batra S, Goggins M, Steidl U, Greally J, Agarwal B, Pradhan K, Banerjee D, Nagrath D*, Maitra A*,&nbsp;&nbsp;<strong>Verma A*.</strong>&nbsp;Lactate-mediated Epigenetic Reprogramming Regulates Formation of Pancreatic Cancer-associated Fibroblasts&nbsp;<strong>Elife,</strong>&nbsp;Oct 30;8, 2019, (In Press)* Equal Contribution&nbsp;PMID: 31663852</li>
<li>Santini V, Valc&aacute;rcel D, Platzbecker U, Komrokji RS, Cleverly AL, Lahn MM, Janssen J, Zhao Y, Chiang A, Giagounidis A, Guba SC, Gueorguieva I, Girvan AC, da Silva Ferreira M, Bhagat TD, Pradhan K, Steidl U, Sridharan A, Will B,&nbsp;<strong>Verma A</strong>.&nbsp;Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes.&nbsp;<strong>Clin Cancer Res</strong>. 2019 Sep 3. PMID: 31481511</li>
<li>Smith M*, Choudhary GS*, Pellagatti A, Choi K, Bhagat TD, Gordon-Mitchell S, Von Ahrens D, Pradhan K, Steeples V , Kim S, Steidl U , Salomonis N , Walter M, Komurov K, Boultwood J*,&nbsp;<strong>Verma A</strong>*, Starczynowski D*<br />
U2AF1 mutations induce oncogenic innate immune pathways by regulating the expression of active IRAK4 isoforms in hematologic malignancies.&nbsp;<strong>Nature Cell Bio</strong>&nbsp;2019&nbsp;May;21(5):640-650&nbsp;* Equal Contribution&nbsp;</li>
<li>Jeong JJ, Gu X, Nie J, Sundaravel S, Liu H, Kuo W, Bhagat TD, Pradhan K, Cao J, Nischal S, McGraw K, Bhattacharyya S, Bishop M, Artz A, Thirman M, Moliterno AR, Ji P, Levine RL, Godley LA, Steidl U, Beiker J, List AF, Saunthararajah Y, He C,&nbsp;<strong>Verma A</strong>,* Wickrema A*<br />
Cytokine regulated phosphorylation and activation of TET2 by JAK2 in hematopoiesis <strong>Cancer Discovery</strong>&nbsp;2019 Jun;9(6):778-795&nbsp;* Equal Contribution</li>
<li>Bhagat TD, Ahrens DV, Dawlaty M, Zou Y, Baddour J, Achreja A, Zhao H, Yang L, Patel N, Kwak C,&nbsp; Choudhary G, Gordon-Mitchell S, Alluri S, Bhattacharyya S, Yu Y, Bartenstein M, Giricz O, Suzuki M, Sohal D, Gupta S, Batra S, Goggins M, Steidl U, Greally J, Agarwal B, Pradhan K, Banerjee D, Nagrath D*, Maitra A*,&nbsp;&nbsp;<strong>Verma A*.</strong>&nbsp;Lactate-mediated Epigenetic Reprogramming Regulates Formation of Pancreatic Cancer-associated Fibroblasts&nbsp;<strong>Elife,</strong>&nbsp;Oct 30;8, 2019, (In Press)* Equal Contribution&nbsp;PMID: 31663852</li>
<li>Santini V, Valc&aacute;rcel D, Platzbecker U, Komrokji RS, Cleverly AL, Lahn MM, Janssen J, Zhao Y, Chiang A, Giagounidis A, Guba SC, Gueorguieva I, Girvan AC, da Silva Ferreira M, Bhagat TD, Pradhan K, Steidl U, Sridharan A, Will B,&nbsp;<strong>Verma A</strong>.&nbsp;Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes.&nbsp;<strong>Clin Cancer Res</strong>. 2019 Sep 3. PMID: 31481511</li>
<li>Smith M*, Choudhary GS*, Pellagatti A, Choi K, Bhagat TD, Gordon-Mitchell S, Von Ahrens D, Pradhan K, Steeples V , Kim S, Steidl U , Salomonis N , Walter M, Komurov K, Boultwood J*,&nbsp;<strong>Verma A</strong>*, Starczynowski D*<br />
U2AF1 mutations induce oncogenic innate immune pathways by regulating the expression of active IRAK4 isoforms in hematologic malignancies.&nbsp;<strong>Nature Cell Bio</strong>&nbsp;2019 May;21(5):640-650&nbsp;* Equal Contribution&nbsp;</li>
<li>Jeong JJ, Gu X, Nie J, Sundaravel S, Liu H, Kuo W, Bhagat TD, Pradhan K, Cao J, Nischal S, McGraw K, Bhattacharyya S, Bishop M, Artz A, Thirman M, Moliterno AR, Ji P, Levine RL, Godley LA, Steidl U, Beiker J, List AF, Saunthararajah Y, He C,&nbsp;<strong>Verma A</strong>,* Wickrema A*<br />
Cytokine regulated phosphorylation and activation of TET2 by JAK2 in hematopoiesis<br />
<strong>Cancer Discovery</strong>&nbsp;2019 Jun;9(6):778-795&nbsp;* Equal Contribution</li>
<li>Chen J, Kao Y, Sun D, Todorova T, Reynolds D, Narayanagari SR, Montagna C, Will B,&nbsp;<strong>Verma A</strong>*, Steidl U*Myelodysplastic Syndrome Progression to Acute Myeloid Leukemia at the Stem Cell Level&nbsp;<strong>Nature Medicine</strong>&nbsp;2018,&nbsp;Jan;25(1):103-110&nbsp;* Equal Contribution</li>
<li>Shastri A, Choudhary G, Teixeira M, Gordon-Mitchell S, Ramachandra N, Bernard L, Bhattacharyya, S. Lopez, R. Pradhan, K. Giricz, O. Ravipati, G. Wong, L. F. Cole, S. Bhagat, T. D. Feld, J. Dhar, Y. Bartenstein, M. Thiruthuvanathan, V. J.&nbsp; Wickrema, A. Ye, B. H. Frank, D. A. Pellagatti, A. Boultwood, J. Zhou, T. Kim, Y. MacLeod, A. R. Epling-Burnette, P. K. Ye, M. McCoon, P. Woessner, R. Steidl, U. Will, B.&nbsp;<strong>Verma, A.&nbsp;</strong>Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells.&nbsp;<strong>J Clin Invest</strong>. 2018 Sep 25. PMID: 30252677</li>
<li>Shah UA, Chung EY, Giricz O, Pradhan K, Kataoka K, Gordon-Mitchell S, Bhagat TD, Mai Y, Wei Y, Ishida E, Choudhary GS, Joseph A, Rice R, Gitego N, Parrish C, Bartenstein M, Goel S, Mantzaris I, Shastri A, Derman O, Binder A, Gritsman K, Kornblum N, Braunschweig I, Bhagat C, Hall J, Graber A, Ratner L, Wang Y, Ogawa S,&nbsp;<strong>Verma A*</strong>, Ye BH*, Janakiram M.* North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies.&nbsp;<strong>Blood.</strong>&nbsp;2018 Aug 13. PMID: 30104217 * Equal Contribution</li>
<li>Landgren O*, Zeig-Owens R*, Giricz O*, Goldfarb D, Murata K, Thoren K, Ramanathan L, Hultcrantz M, Dogan A, Nwankwo G, Steidl S, Pradhan K, Hall C, Cohen HW, Jaber N, Schwartz T, Crowley L, Crane M, Irby S, Webber MP,&nbsp;<strong>Verma A*</strong>, Prezant DJ* Multiple Myeloma and Its Precursor Disease among Firefighters Exposed to the World Trade Center Disaster&nbsp;<strong>JAMA Onc</strong>, 2018 Jun 1;4(6):821-827. PMID: 29710195 &nbsp;* Equal Contribution</li>
<li>Kao YR, Chen J, Narayanagari SR, Todorova TI, Aivalioti MM, Ferreira M, Ramos PM, Pallaud C, Mantzaris I, Shastri A, Bussel JB,&nbsp;<strong>Verma A</strong>, Steidl U, Will B. Thrombopoietin receptor-independent stimulation of hematopoietic stem cells by eltrombopag.&nbsp;<strong>Sci Transl Med</strong>. 2018 Sep 12;10(458). PMID: 30209246</li>
<li>Giricz O, Mo Y, Dahlman KB, Cotto-Rios XM, Vardabasso C, Nguyen H, Matusow B, Bartenstein M, Polishchuk V, Johnson DB, Bhagat TD, Shellooe R, Burton E, Tsai J, Zhang C, Habets G, Greally JM, Yu Y, Kenny PA, Fields GB, Pradhan K, Stanley ER, Bernstein E, Bollag G, Gavathiotis E, West BL, Sosman JA,&nbsp;<strong>Verma AK&nbsp;</strong>The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma.&nbsp;<strong>JCI Insight</strong>. 2018 Jul 25;3(14). PMID: 30046005</li>
<li>Carvajal LA, Ben-Neriah D, Senecal A, Benard L, Thiruthuvanathan V, Yatsenko T, Narayanagari SR, Wheat JC, Todorova TI, Mitchell KM, Kenworthy C, Guerlavais V, Annis DA, Bartholdy B, Will B, Anampa JD, Mantzaris I, Aivado M, Singer RH, Coleman RA,&nbsp;<strong>Verma A</strong>, Steidl U. Dual inhibition of MDMX and MDM2 as a Therapeutic Strategy in Leukemia.&nbsp;<strong>Sci Transl Med</strong>.&nbsp;2018, Apr 11;10(436). PMID: 29643228</li>
<li>Mitchell K, Barreyro L, Todorova TI, Taylor SJ, Antony-Debr&eacute; I, Narayanagari SR, Carvajal LA, Leite J, Piperdi Z, Pendurti G, Mantzaris I, Paietta E,&nbsp;<strong>Verma A</strong>, Gritsman K, Steidl U.&nbsp; IL1RAP potentiates multiple oncogenic signaling pathways in AML.&nbsp;<strong>J Exp Med.</strong>&nbsp;2018 Jun 4;215(6):1709-1727 PMID: 29773641</li>
<li>Bhattacharyya S, Pradhan K, Campbell N, Mazdo J, Vasantkumar A, Maqbool S, Bhagat TD, Gupta S, Suzuki M, Yu Y, Greally JM, Steidl U, Bradner J, Dawlaty M, Godley L, Maitra A,&nbsp;<strong>Verma A,&nbsp;</strong>&ldquo;Altered hydroxymethylation is seen at regulatory regions in pancreatic cancer and regulates oncogenic pathways,&rdquo; &nbsp;<strong>Genome Res</strong>, 2017, Oct 6. PMID: 28986391</li>
<li>Bhagat TD, Chen S, Bartenstein M, Barlowe AT, Von Ahrens D, Choudhary GS, Tivnan P, Amin E, Marcondes M, Sanders MA, Hoogenboezem RM, Kambhampati S, Ramachandra N, Mantzaris I, Sukrithan V, Laurence R, Lopez R, Bhagat P, Giricz O, Sohal D, Wickrema A, Yeung C, Gritsman K, Aplan P, Hochedlinger K, Yu Y, Pradhan K, Zhang J, Greally JM,&nbsp; Mukherjee SM, Pellagatti A, Boultwood J, Will B, Steidl U, Raaijmakers MHGP, Deeg HJ, Kharas MG,&nbsp;<strong>Verma A,&nbsp;</strong>&ldquo;Wnt/&szlig;-catenin activation by epigenetically aberrant stroma drives myelodysplastic syndrome,&rdquo;&nbsp;<strong>Cancer Research</strong>&nbsp;Jul, 2017, PMID: 28684528</li>
<li>Reyna DE, Garner TP, Lopez A, Kopp F, Choudhary GS, Sridharan A, Narayanagari SR, Mitchell K, Dong B, Bartholdy BA, Walensky LD,&nbsp;<strong>Verma A</strong>, Steidl U, Gavathiotis E. Direct &ldquo;Activation of BAX by BTSA1 Overcomes Apoptosis Resistance in Acute Myeloid Leukemia,&rdquo;&nbsp;&nbsp;<strong>Cancer Cell</strong>&nbsp;2017 Oct 9.PMID: 29017059&nbsp;</li>
<li>Antony-Debr&eacute; I, Paul A, Leite J, Mitchell K, Kim HM, Carvajal LA, Todorova TI, Huang K, Kumar A, Farahat AA, Bartholdy B, Narayanagari SR, Chen J, Ambesi-Impiombato A, Ferrando AA, Mantzaris I, Gavathiotis E,&nbsp;<strong>Verma A</strong>, Will B, Boykin DW, Wilson WD, Poon GM, Steidl U., &ldquo;Pharmacological inhibition of the transcription factor PU.1 in leukemia,&rdquo; &nbsp;<strong>J Clin Invest</strong>&nbsp;2017 Oct 30, PMID: 29083320</li>
<li>Yue L, Bartenstein M, Zhao W, Ho W, Murdun C, Mailloux AW, Zhang L, Budhakoti A, Pradhan K, Rapaport F, Wang H, Shao Z, Steidl U, Levine RL, Zhao ZJ,&nbsp;<strong>Verma A*,</strong>&nbsp;Epling-Burnette PK* (*Co-Corresponding), &ldquo;Efficacy of ALK5 Inhibition in Myelofibrosis.&rdquo;&nbsp;&nbsp;&nbsp;<strong>JCI Insight&nbsp;</strong>(In Press)</li>
<li>Bhagat TD, Zou Y, Huang S, Park J, Palmer MB, Hu C, Li W, Shenoy N, Giricz O, Choudhary G, Yu Y, Ko YA, Izquierdo MC, Park ASD, Vallumsetla N, Laurence R, Lopez R, Suzuki M, Pullman J, Kaner J, Gartrell B, Hakimi AA, Greally JM, Patel B, Benhadji K, Pradhan K,&nbsp;<strong>Verma A*,</strong>&nbsp;Susztak K* (*Co-Corresponding), &ldquo;Notch pathway is activated via genetic and epigenetic alterations and is a therapeutic target in clear cell renal cancer .&rdquo; &nbsp;<strong>JBC&nbsp;</strong>2016, Dec 1. PMID: 2790905</li>
<li>Bachegowda L, Morrone K, Winski SL, Mantzaris I, Bartenstein M, Ramachandra N, Giricz O, Sukrithan V, Nwankwo G, Shahnaz S , Bhagat T, Bhattacharyya S, Assal A, Shastri A,&nbsp; Gordon-Mitchell S, Pellagatti A, Boultwood J, Schinke C, Yu Y, Guha C, Rizzi J, Garrus J, Brown S, Wollenberg L, Hogeland G, Wright D, Munson M`, Rodriguez M, Gross S, Chantry D, Zou Y, Platanias L, Burgess LE, Pradhan K, Steidl U,&nbsp;<strong>Verma A,</strong>&nbsp; &ldquo;Pexmetinib: a novel dual inhibitor of Tie-2 and p38 MAPK with efficacy in preclinical models of myelodysplastic syndromes and acute myeloid leukemia.&rdquo;&nbsp;&nbsp;<strong>Cancer Res&nbsp;</strong>2016 Jun 10. PMID: 27287719</li>
<li>Goel S, Hall J, Pradhan K, Hirsch C, Przychodzen B, Shastri A, Mantzaris I,&nbsp; Janakiram M, Battini R, Kornblum N, Derman O, Gritsman K, Al-Hafidh J, Wang Y, Halmos B, Steidl U, Maciejewski J, Braunschweig I,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;High Prevalence and Allele Burden Independent Prognostic Importance of p53 Mutations in an Inner-City MDS/AML Cohort,&rdquo; &nbsp;<strong>Leukemia&nbsp;</strong>2016 Apr 29. PMID: 27125205</li>
<li>Taggart J, Ho TC, Amin E, Xu H, Barlowe TS, Perez AR, Durham BH, Tivnan P, Okabe R, Chow A, Vu L, Park SM, Prieto C, Famulare C, Patel M, Lengner CJ,&nbsp;<strong>Verma A,</strong>&nbsp;Roboz G, Guzman M, Klimek VM, Abdel-Wahab O, Leslie C, Nimer SD, Kharas MG. &ldquo;MSI2 is required for maintaining activated myelodysplastic syndrome stem cells.&rdquo;&nbsp;&nbsp;<strong>Nat Commun.</strong>&nbsp;2016 Feb 22;7:10739. PMID: 26898884</li>
<li>Platzbecker U, Wong RS,&nbsp;<strong>Verma A,</strong>&nbsp;Abboud C, Araujo S, Chiou TJ, Feigert J, Yeh SP, G&ouml;tze K, Gorin NC, Greenberg P, Kambhampati S, Kim YJ, Lee JH, Lyons R, Ruggeri M, Santini V, Cheng G, Jang JH, Chen CY, Johnson B, Bennett J, Mannino F, Kamel YM, Stone N, Dougherty S, Chan G, Giagounidis A., &ldquo;Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.&rdquo;&nbsp;&nbsp;<strong>Lancet Haematol.</strong>&nbsp;2015 Oct;2(10):e417-26. PMID: 26686043</li>
<li>Sundaravel S, Duggan R, Bhagat TD, Ebenezer D, Liu H, Yu Y, Bartenstein M, Unnikrishnan M, Karmakar S, Liu TC, Anastasi J, McGraw K, Pellagatti A, Boultwood J, Yajnik V, Artz A, Le Beau M, Steidl U, List A, Evans T*,&nbsp;<strong>Verma A</strong>*, Wickrema A*. (*Co-Corresponding),&nbsp; &ldquo;Reduced DOCK4 Expression Leads to Erythroid Dysplasia in Myelodysplastic Syndromes.&rdquo;&nbsp;&nbsp;<strong>PNAS</strong>&nbsp;2015; Nov 17;112(46): PMID: 26578796</li>
<li>Okoye-Okafor UC, Bartholdy B, Cartier J, Gao EN, Pietrak B, Rendina AR, Rominger C, Quinn C, Smallwood A, Wiggall KJ, Reif AJ, Schmidt SJ, Qi H, Zhao H, Joberty G, Faelth-Savitski M, Bantscheff M, Drewes G, Duraiswami C, Brady P, Groy A, Narayanagari SR, Antony-Debre I, Mitchell K, Wang HR, Kao YR, Christopeit M, Carvajal L, Barreyro L, Paietta E, Makishima H, Will B, Concha N, Adams ND, Schwartz B, McCabe MT, Maciejewski J,&nbsp;<strong>Verma A,</strong>&nbsp;Steidl U., &ldquo;New IDH1 mutant inhibitors for treatment of acute myeloid leukemia.&rsquo;&nbsp;<strong>Nature Chem Biol</strong>. 2015 Oct 5. PMID: 26436839</li>
<li>PAK1 Pandolfi A, Stanley RF, Yu Y, Bartholdy B, Pendurti G, Gritsman K, Boultwood J, Chernoff J,&nbsp;<strong>Verma A,</strong>&nbsp;Steidl U, &ldquo;PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome.&rdquo;&nbsp;<strong>Blood.</strong>&nbsp;2015 Jul 13. PMID: 26170031</li>
<li>Cabrero M, Yu Y,&nbsp;<strong>Verma A,</strong>&nbsp;Yang H, Colla S, Jia Y, Zheng H, Bohannan Z, Ganan-Gomez I, Futreal A, Takahashi K, Chin L, Kantarjian H, Pellagatti A, Bowman T, Boultwood J, Garcia-Manero G, Wei Y, &ldquo;Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion.&rdquo;&nbsp;<strong>Br J Haematol.</strong>&nbsp;2015 Jun 24. PMID: 26105212</li>
<li>Vardabasso C, Gaspar-Maia A, Hasson D, P&uuml;nzeler S, Valle-Garcia D, Straub T, Keilhauer EC, Strub T, Dong J, Panda T, Chung CY, Yao JL, Singh R, Segura MF, Fontanals-Cirera B,&nbsp;<strong>Verma A,</strong>&nbsp;Mann M, Hernando E, Hake SB, Bernstein E, &ldquo;Histone Variant H2A.Z.2 Mediates Proliferation and Drug Sensitivity of Malignant Melanoma.&rdquo;&nbsp;<strong>Mol Cell.</strong>&nbsp;2015 Jun 3. PMID: 26051178</li>
<li>Sassano A, Mavrommatis E, Arslan AD, Kroczynska B, Beauchamp EM, Khuon S, Chew TL, Green KJ, Munshi HG,&nbsp;<strong>Verma AK,</strong>&nbsp;Platanias LC, &ldquo;Human Schlafen 5 (SLFN5) is a Regulator of Motility and Invasiveness of Renal Cell Carcinoma&nbsp; Cells.&rdquo;&nbsp;<strong>Mol Cell Biol.</strong>&nbsp;2015 May 26. PMID: 26012550</li>
<li>Saleiro D, Mehrotra S, Kroczynska B, Beauchamp EM, Lisowski P, Majchrzak-Kita B, Bhagat TD, Stein BL, McMahon B, Altman JK, Kosciuczuk EM, Baker DP, Jie C, Jafari N, Thompson CB, Levine RL, Fish EN,&nbsp;<strong>Verma A,</strong>&nbsp;Platanias LC, &ldquo;Central Role of ULK1 in Type I Interferon Signaling.&rdquo;&nbsp;<strong>Cell Reports</strong>&nbsp;2015, Apr 28;11(4):605-17. PMID: 25892232</li>
<li>Cimmino L, Dawlaty MM, Ndiaye-Lobry D, Yap YS, Bakogianni S, Yu Y, Bhattacharyya S, Shaknovich R, Geng H, Lobry C, Mullenders J, King B, Trimarchi T, Aranda-Orgilles B, Liu C, Shen S,&nbsp;<strong>Verma A,</strong>&nbsp;Jaenisch R, Aifantis I, &ldquo;TET1 is a tumor suppressor of hematopoietic malignancy.&rdquo;&nbsp;<strong>Nat Immunol.</strong>&nbsp;2015 Apr 13. PMID: 25867473</li>
<li>Schinke C, Giricz O, Li W, Shastri A, Gordon S, Barreryo L, Bhagat T, Bhattacharyya S, Ramachandra N, Bartenstein M, Pellagatti A, Boultwood J, Wickrema A, Yu Y, Will W, Wei S, Steidl U*,&nbsp;<strong>Verma A*,&nbsp;</strong>&nbsp; *co-corresponding authors, &ldquo;IL8-CXCR2 pathway inhibition as a novel therapeutic strategy against MDS and AML stem cells.&rdquo;&nbsp;<strong>Blood.</strong>&nbsp;2015, Mar 25. PMID: 25810490&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>Gerstung M, Pellagatti A, Malcovati L, Giagounidis A, Porta MG, J&auml;dersten M, Dolatshad H,&nbsp;<strong>Verma A,</strong>&nbsp;Cross NC, Vyas P, Killick S, Hellstr&ouml;m-Lindberg E, Cazzola M, Papaemmanuil E, Campbell PJ, Boultwood J, &ldquo;Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic Syndromes.&rdquo;&nbsp;<strong>Nat Commun.</strong>&nbsp;2015 Jan 9;6:5901. PMID: 25574665&nbsp;</li>
<li>Caescu CI, Guo X, Tesfa L, Bhagat TD,&nbsp;<strong>Verma A,</strong>&nbsp;Zheng D, Stanley ER, &ldquo;Colony stimulating factor-1 receptor signaling networks inhibit mouse macrophage inflammatory responses by induction of microRNA-21.&rdquo;&nbsp;<strong>Blood.</strong>&nbsp;2015 Jan 8. PMID: 25573988</li>
<li>Will B, Vogler TO, Narayanagari S, Bartholdy B, Todorova TI, Ferreira M, Chen J, Yu Y, Mayer J, Barreyro L, Carvajal L, Ben Neriah D, Roth M, van Oers J, Schaetzlein S, McMahon C, Edelmann W,&nbsp;<strong>Verma A,</strong>&nbsp;Steidl U, &ldquo;Minimal reduction of PU.1 is sufficient to induce a preleukemic state and promote development of acute myeloid leukemia.&rdquo;&nbsp;<strong>Nature Medicine,</strong>&nbsp;2015 (In Print)</li>
<li>Shrivastava MS, Hussain Z, Giricz O, Shenoy N, Polineni R, Maitra A,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;Targeting chemokine pathways in esophageal adenocarcinoma.&rdquo;&nbsp;<strong>Cell Cycle.</strong>&nbsp;2014 Nov 1;13(21):3320-7. PMID: 25485576</li>
<li>Hu C, Mohtat D, Yu Y, Ko YA, Shenoy N, Bhattacharyya S, Izquierdo MC, Park AS, Giricz O, Vallumsetla N, Gundabolu K, Ware K, Bhagat T, Suzuki M, Pullman J, Liu SX, Greally J, Susztak K,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;Kidney cancer is characterized by aberrant methylation of tissue specific enhancers that are prognostic for overall survival.&rdquo;&nbsp;<strong>Clin Cancer Res.</strong>&nbsp;2014 Jun 10. PMID: 24916699</li>
<li>Mariani CJ, Vasanthakumar A, Madzo J, Yesilkanal A, Bhagat T, Yu Y, Bhattacharyya S, Wenger R, Cohn S, Nanduri J,&nbsp;<strong>Verma A,</strong>&nbsp;Prabhakar N, Godley LA, &ldquo;TET1-Mediated Hydroxymethylation Facilitates Hypoxic Gene Induction in Neuroblastoma.&rdquo;&nbsp;<strong>Cell Rep.</strong>&nbsp;2014 May 14. PMID: 24835990</li>
<li>Keerthivasan G, Mei Y, Zhao B, Zhang L, Harris CE, Gao J, Basiorka AA, Schipma MJ, McElherne J, Yang J,&nbsp;<strong>Verma AK,</strong>&nbsp;Pellagatti A, Boultwood J, List AF, Williams DA, Ji P., &ldquo;Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) myelodysplastic syndromes.&rdquo;&nbsp;<strong>Blood.</strong>&nbsp;2014 Jun 2. PMID: 24891322</li>
<li>Tamari R,&nbsp; Schinke C, Bhagat T, Roth M, Braunschweig I,&nbsp; Will B,&nbsp; Steidl U,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone.&rdquo;&nbsp;<strong>Leuk Lymphoma,</strong>&nbsp;2014 Dec;55(12):2901-6.PMID: 24650011</li>
<li>Bartholdy B, Christopeit M, Will B, Mo Y, Barreyro L, Yu Y, Bhagat T, Okoye-Okafor U, Todorova T, Greally J, Levine RL, Melnick A,&nbsp;<strong>Verma A*,</strong>&nbsp;Steidl U, *Co-Corresponding, &ldquo;A human hematopoietic stem cell-commitment related DNA cytosine methylation signature is prognostic for overall survival in acute myeloid leukemia.&rdquo;&nbsp;<strong>Journal of Clinical Investigation</strong>&nbsp;2014 Feb 3 PMID: 24487588</li>
<li>Kuo P, Leshchenko V, Fazzari M, Gellen T, Iqbal J, Baumgartner-Wennerholm S, Nygren L, Zhang F, Zhang W, Suh K, Goy A, Yang D, Chan W, Kahl B,&nbsp;<strong>Verma A,</strong>&nbsp;Gascoyne R, Kimby E, Sander B, Ye BH, Melnick A, Perumal D, He T, Parekh S, &ldquo;High resolution Chromatin Immunoprecipitation (ChIP) sequencing reveals novel bindings targets and prognostic role for SOX11 in Mantle cell lymphoma.&rdquo;<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oncogene,</strong>&nbsp;2014 Mar 31 PMID: 24681958</li>
<li>Hosono N, Makishima H, Jerez A, Yoshida K, Przychodzen B, McMahon S, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Sanada M, G&oacute;mez-Segu&iacute; I,&nbsp;<strong>Verma AK,</strong>&nbsp;McDevitt MA, Sekeres MA, Ogawa S, Maciejewski JP, &ldquo;Recurrent genetic defects on chromosome 7q in myeloid neoplasms.&rdquo;<strong>Leukemia</strong>&nbsp;2014 Jan 16. PMID: 24429498</li>
<li>Madzo J, Liu H, Rodriguez A, Vasanthakumar A, Sundaravel S, Caces DB, Looney TJ, Zhang L, Lepore JB, Macrae T, Duszynski R, Shih AH, Song CX, Yu M, Yu Y, Grossman R, Raumann B,&nbsp;<strong>Verma A,</strong>&nbsp;He C, Levine RL, Lavelle D, Lahn BT, Wickrema A, Godley LA, &ldquo;Hydroxymethylation at Gene Regulatory Regions Directs Stem/Early Progenitor Cell Commitment during Erythropoiesis.&rdquo;&nbsp;<strong>Cell Reports</strong>&nbsp;2013 Dec 24 PMID: 24373966</li>
<li>Ko YA, Mohtat D, Suzuki M, Park AS, Izquierdo MC, Han SY, Kang HM, Si H, Hostetter T, Pullman JM, Fazzari M,&nbsp;<strong>Verma A,</strong>&nbsp;Zheng D, Greally JM, Susztak K, &ldquo;Cytosine methylation changes in enhancer regions of core pro-fibrotic genes characterize kidney fibrosis development.&rdquo;&nbsp;<strong>Genome Biol.</strong>&nbsp;2013 Oct 7;14(10):R108. PMID: 24098934</li>
<li>Pellagatti A, Benner A, Mills K, Cazzola M, Giagounidis AAN, Perry J, Malcovati L, Giovanni M, Porta D, J&auml;dersten M,&nbsp;&nbsp;<strong>Verma A,</strong>&nbsp;McDonald E, Killick S, Hellstrom-Lindberg E, Bullinger L, Wainscoat JS, Boultwood J, &ldquo;Identification of gene expression based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes.&rdquo;&nbsp;<strong>JCO</strong>&nbsp;2013 Oct 1;31(28):3557-64. PMID: 24002510</li>
<li>Lam AP, Gundabolu K, Sridharan A, Jain R, Msaouel P, Chrysofakis G, Yu Y, Friedman E, Price E, Schrier S,&nbsp;<strong>Verma AK,&nbsp;</strong>&nbsp;&ldquo;Multiplicative interaction between mean corpuscular volume and red cell distribution width in predicting mortality of elderly patients with and without anemia.&rdquo;&nbsp;&nbsp;<strong>Am J Hematol.</strong>&nbsp;2013 Nov;88(11):E245-9. PMID: 23828763</li>
<li>Yang X, Song JH, Cheng Y, Wu W, Bhagat T, Yu Y, Abraham JM, Ibrahim S, Ravich Roland W, Khashab M, Singh VK, Shin EJ, Yang X, Verma&nbsp;<strong>A,</strong>&nbsp;Meltzer SJ, Mori Y, &ldquo;Long Noncoding RNA HNF1A-AS1 Regulates Proliferation and Migration in Esophageal Adenocarcinoma Cells.&rdquo;&nbsp;<strong>Gut</strong>&nbsp;2013 Sep 2. PMID: 24000294&nbsp;</li>
<li>Bajpai M, Kessel R, Bhagat T, Nischal S, Yu Y,&nbsp;<strong>Verma A*,</strong>&nbsp;Das K, *Co-Corresponding,&nbsp; &ldquo;High resolution integrative analysis reveals widespread genetic and epigenetic changes after chronic in-vitro acid and bile exposure in Barrett's epithelium cells.&rdquo;&nbsp;<strong>Genes Chromosome Cancer</strong>&nbsp;2013 Oct 3. PMID: 24123713</li>
<li>Mehrotra S, Sharma B, Joshi S, Kroczynska B, Majchrzak B, Stein BL, McMahon B, Altman JK, Licht JD, Baker DP, Eklund EA, Wickrema A,&nbsp;<strong>Verma A,</strong>&nbsp;Fish EN, Platanias LC, &ldquo;Essential role for the Mnk-pathway in the inhibitory effects of Type I interferons on myeloproliferative neoplasm (MPN) precursors.&rdquo;&nbsp;&nbsp;<strong>JBC,</strong>&nbsp;2013 Aug 16;288(33):23814-22 PMID: 23814052</li>
<li>Bhattacharyya, Si; Yu, Y; Suzuki, M; Campbell, N; Mazdo, J; Vasantkumar, A; Bhagat, T; Nischal, S; Christopeit, M; Parekh, S; Steidl, U; Godley, L; Maitra, A; Greally, J;&nbsp;<strong>Verma, A;&nbsp;</strong>&nbsp;&ldquo;Genome wide hydroxymethylation tested using the HELP-GT assay shows redistribution in cancer.&rdquo;&nbsp;<strong>Nucleic Acid Res</strong>&nbsp;2013&nbsp; Sep;41(16):e157 PMID: 23861445</li>
<li>Will B, Vogler TO, Bartholdy B, Garrett-Bakelman F, Mayer J, Barreyro L, Pandolfi A, Todorova TI, Okoye-Okafor UC, Stanley RF, Bhagat TD,&nbsp;<strong>Verma A,</strong>&nbsp;Figueroa ME, Melnick A, Roth M, Steidl U, &ldquo;Satb1 regulates the self-renewal of hematopoietic stem cells by promoting quiescence and repressing differentiation commitment.&rdquo;&nbsp;<strong>Nat Immunol.</strong>&nbsp;2013 May;14(5):437-45. PMID: 23563689</li>
<li>Bhagat T, Zhou L, Sokol L, Caceres G, Gundabolu K, Gordon S, Mantzaris I, Gligich O, Yu Y, Bhattacharyya S, Jing X, Polineni R, Tamari R, Bhatia K, Pellagatti A , Boultwood J, Kambhampati S, Steidl U, Stein C, Ju W, Liu G, Kenny P, List A, Bitzer M,&nbsp;<strong>Verma A,&nbsp;</strong>&nbsp;&ldquo;miR-21 mediates hematopoietic suppression in MDS by activating TGF-bsignaling.&rdquo;&nbsp;<strong>Blood</strong>&nbsp;2013, Apr 11;121(15):2875-81. PMID: 23390194</li>
<li>Yu Y, Mo Y, Liu H, Bhattacharyya S, Ebenezer D, Sundaravel S, Caces B, Ulaszek J, Artz A, Nischal S, Bhagat T, Bathon K, Maqbool S, Suzuki M, Steidl U, Godley L, Skoultchi A, Greally J, Wickrema A,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;High resolution methylome analysis reveals widespread hypomethylation during human erythroid differentiation.&rdquo;&nbsp;<strong>JBC</strong>&nbsp;2013 Mar 29;288(13):8805-14. PMID: 23306203</li>
<li>Heuck C, Mehta J, Bhagat T, Gundabolu K, Yu Y, Khan S, Chrysofakis G, Schinke C, Tariman J, Vickrey E, Pulliam N, Nischal S, Zhou L, Bhattacharya S, Meagher R, Hu C, Maqbool S, Suzuki M, Parekh S, Reu F, Steidl U, Greally J,<strong>&nbsp;Verma A*,</strong>&nbsp;Singhal S,* Co-Corresponding, &ldquo;Myeloma is characterized by stage specific alterations in DNA methylation that occur early during myelomagenesis.&rdquo; &nbsp;<strong>Journal of Immunology</strong>&nbsp;2013 Mar 15;190(6):2966-75. PMID: 23408834</li>
<li>Wu W, Bhagat T, Yang X, Song J, Cheng Y, Agarwal R, Abraham J, Ibrahim S, Bartenstein M, Hussain Z, Suzuki M, Yu Y, Eng C, Greally J,&nbsp;<strong>Verma A*,</strong>&nbsp;Meltzer SJ*, Co-Corresponding, &ldquo;Hypomethylation of Noncoding DNA Regions and Overexpression of the Long Noncoding RNA, AFAP1-AS1, in Barrett&rsquo;s Esophagus and Esophageal Adenocarcinoma.&rdquo;&nbsp;<strong>Gastroenterology</strong>&nbsp;2013 May;144(5):956-966. PMID: 23333711</li>
<li>Nischal S, Bhattacharyya S, Christopeit N, Yu Y, Zhou L, Bhagat T, Sohal S, Will B, Mo Y, Suzuki M, Pardanani A, McDevitt M, Maciejewski J, Melnick A, Greally J, Steidl U, Moliterno A,&nbsp;<strong>Verma A,&nbsp;</strong>&nbsp;&ldquo;Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms.&rdquo;&nbsp;<strong>Cancer Res,</strong>&nbsp;2012 Dec 27. PMID: 23066032</li>
<li>Will B, Zhou L, Vogler TO, Ben-Neriah S, Schinke C,Tamari R, Yu Y, Bhagat T,&nbsp; Bhattacharya S, Barreyro L, Heuck C, Mo Y, Parekh S, McMahon C, Pellagatti A, Boultwood J, Montagna C, Silverman L, Maciejewski J, Greally JM, Ye BH, List AF, Steidl C, Steidl U,&nbsp;<strong>Verma A,&nbsp;</strong>&nbsp;&ldquo;Stem and progenitor cells in myelodysplastic syndromes show aberrant stage specific expansion and harbor genetic and epigenetic alterations.&rdquo;&nbsp;<strong>Blood</strong>&nbsp;2012; 120(10):2076-86. PMID: 22753872</li>
<li>Sokol L, Cripe L, Kantarjian H, Sekeres MA, Parmar S, Greenberg P, Goldberg SL, Bhushan V, Shammo J, Hohl R,&nbsp;<strong>Verma A,</strong>&nbsp;Garcia-Manero G, Li YP, Lowe A, Zhu J, List AF, &ldquo;Randomized, dose-escalation study of the p38&alpha; MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome.&rdquo;&nbsp;<strong>Leukemia.</strong>&nbsp;2012 Sep 11. PMID: 23032694</li>
<li>Barreyro L, Will B, Bartholdy B, Zhou L, Todorova TI, Stanley RF, Ben-Neriah S, Montagna C, Parekh S, Pellagatti A, Boultwood J, Paietta E, Ketterling RP, Cripe L, Fernandez, Greenberg PL, Tallman MS, Steidl C, Mitsiades CS,&nbsp;<strong>Verma A,</strong>&nbsp;Steidl U, &ldquo;Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.&rdquo;&nbsp;<strong>Blood.</strong>&nbsp;2012 Aug 9;120(6):1290-8. PMID: 22723552</li>
<li>Jerez A, Sugimoto Y, Makishima H,&nbsp;<strong>Verma A,</strong>&nbsp;Jankowska AM, Przychodzen B, Visconte V, Tiu RV, O'Keefe CL, Mohamedali AM, Kulasekararaj AG, Pellagatti A, McGraw K, Muramatsu H, Moliterno AR, Sekeres MA, McDevitt MA, Kojima S, List A, Boultwood J, Mufti GJ, Maciejewski JP,&nbsp; &ldquo;Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis.&rdquo;&nbsp;&nbsp;&nbsp;<strong>Blood.</strong>&nbsp;2012 Jun 21;119(25):6109-17. PMID: 22553315</li>
<li>Roth M, Will B, Simkin G, Narayanagari S, Barreyro L, Bartholdy B, Tamari R, Mitsiades CS,&nbsp;<strong>Verma A,</strong>&nbsp;Steidl U., &ldquo;Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation.&rdquo;&nbsp;<strong>Blood.</strong>&nbsp;2012 May 24. PMID: 22627766</li>
<li>Barta SK, Zou Y, Schindler J, Shenoy N, Bhagat TD, Steidl U,&nbsp;<strong>Verma A.,</strong>&nbsp;&ldquo;Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia.&rdquo;&nbsp;<strong>Leuk Lymphoma</strong>.2012 Apr 18.&nbsp; PMID: 22448921</li>
<li>Stein BL, Williams DM, O'Keefe C, Rogers O, Ingersoll RG, Spivak JL,<strong>&nbsp;Verma A,</strong>&nbsp;Maciejewski JP, McDevitt MA, Moliterno AR, &ldquo;Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes.&rdquo;&nbsp;&nbsp;&nbsp;<strong>Haematologica.</strong>&nbsp;2011 Oct;96(10):1462-9. Epub 2011 Jun 28. PMID: 21712540</li>
<li>Sharma B, Altman JK, Goussetis DJ,&nbsp;<strong>Verma AK,</strong>&nbsp;Platanias LC, &ldquo;Protein kinase R as mediator of the effects of interferon (IFN) gamma and tumor necrosis factor (TNF) alpha on normal and dysplastic hematopoiesis.&rdquo;&nbsp;<strong>J Biol Chem.</strong>&nbsp;2011 Aug 5;286(31):27506-14. Epub 2011 Jun 9. PMID:1659535</li>
<li>Zhou L, Opalinska J, Sohal D, Yu Y, Mo Y, Bhagat T, Abdel-Wahab O, Fazzari M, Figueroa M, Alencar C, Zhang J, Kanbhampati S, Parmar S, Nischal S, Heuck C, Suzuki M, Friedman E, Pellagatti A, Boultwood J, Steidl U, Sauthararajah Y, Yajnik V, Gore SD, Platanias LC, Levine R, Melnick A, Wickrema A, Greally JM,&nbsp;<strong>Verma A,&nbsp;</strong>&nbsp;&ldquo;Aberrant epigenetic and genetic marks are seen in myelodysplastic leucocytes and reveal DOCK4 as a candidate pathogenic gene on chr7q.&rdquo;&nbsp;<strong>J Biol Chem.</strong>&nbsp;2011 Apr 30. PMID: 21532034&nbsp;</li>
<li>Alvarez H, Opalinska J, Zhou L, Sohal D, Fazzari M, Yu Y, Montagna C, Montgomery E, Canto M, Dunbar K, Wang J, Roa J, Mo Y, Bhagat T, Ramesh K, Cannizzaro L, Mollenhauer J, Thompson R, Suzuki M, Meltzer S, Melnick A, Greally JM, Maitra A,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis.&rdquo;&nbsp;<strong>PLOS Genetics</strong>&nbsp;2011 Mar;7(3) PMID: 21483804</li>
<li>L Zhou, C McMahon, T Bhagat, C Alencar, Y Yu, M Fazzari, D Sohal, C Heuck, K Gundabolu, C Ng, Y Mo, W Shen, A Wickrema, G Kong, E Friedman, L Sokol,&nbsp; G Mantzaris, A Pellagatti , J Boultwood, LC Platanias, U Steidl, L Yan, JM Yingling, MM Lahn, A List, M Bitzer and&nbsp;<strong>A Verma,</strong>&nbsp;&ldquo;Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase.&rdquo;&nbsp;<strong>Cancer Research</strong>&nbsp;2011 Feb 1;71(3):955-63.PMID: 21189329</li>
<li>Joshi S, Sharma B, Kaur S, Majchrzak B, Ueda T, Fukunaga R,<strong>&nbsp;Verma AK,</strong>&nbsp;Fish EN, Platanias LC, &ldquo;Essential role for Mnk kinases in type II interferon (IFNgamma) signaling and its suppressive effects on normal hematopoiesis.&rdquo;&nbsp;&nbsp;<br />
<strong>J Biol Chem.</strong>&nbsp;2011 Feb 25;286(8):6017-26.PMID: 21149447</li>
<li>Kroczynska B, Joshi S, Eklund EA,&nbsp;<strong>Verma A,</strong>&nbsp;Kotenko SV, Fish EN, Platanias LC, &ldquo;Regulatory effects of ribosomal S6 kinase 1 (RSK1) in IFN&lambda; signaling.&rdquo;&nbsp;<strong>J Biol Chem.</strong>&nbsp;2011 Jan 14;286(2):1147-56. Epub 2010 Nov 12.</li>
<li>Schinke C, Goel S, Bhagat TD, Zhou L, Mo Y, Gallagher R, Kabalka GW, Platanias LC,&nbsp;<strong>Verma A*,</strong>&nbsp;Das B, &ldquo;Design and synthesis of novel derivatives of all-trans retinoic acid demonstrate the combined importance of acid moiety and conjugated double bonds in its binding to PML-RAR-alpha oncogene in acute promyelocytic leukemia.&rdquo;&nbsp;<br />
<strong>Leuk Lymphoma.</strong>&nbsp;2010 Jun;51(6):1108-14. PMID: 20536349</li>
<li>Huh J, Tiu RV, Gondek LP, O'Keefe CL, Jasek M, Makishima H, Jankowska AM, Jiang Y,&nbsp;<strong>Verma A,</strong>&nbsp;Theil KS, McDevitt MA, Maciejewski JP, &ldquo;Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis.&rdquo;&nbsp;<strong>Genes Chromosomes Cancer.</strong>&nbsp;2010 Apr;49(4):390-9. PMID: 20095039</li>
<li>Pellagatti A, Cazzola M, Giagounidis A, Perry J, Malcovati L, Della Porta MG, J&auml;dersten M,&nbsp;<strong>Verma A,</strong>&nbsp;Norbury C Hellstr&ouml;m-Lindberg E, Wainscoat JS, Boultwood J, &ldquo;Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.&rdquo;&nbsp;<strong>Leukemia.</strong>&nbsp;2010 Apr;24(4):756-64. PMID: 20220779</li>
<li>Einstein F, Thompson RF, Bhagat TD, Fazzari MJ,&nbsp;<strong>Verma A,</strong>&nbsp;Barzilai N, Greally JM, &ldquo;Cytosine methylation dysregulation in neonates following intrauterine growth restriction.&rdquo;&nbsp;<strong>PLoS One.</strong>&nbsp;2010 Jan 26;5(1):e8887 PMID: 20126273</li>
<li>Oda M., Glass J.L., Thompson R.F., Mo Y., Olivier E., Figueroa M.E., Selzer R.R., Richmond T.A., Zhang X., Dannenberg L., Green R., Melnick A., Hatchwell E., Bouhassira E.,&nbsp;<strong>Verma A.,</strong>&nbsp;Suzuki M., Greally J.M., &ldquo;High-resolution genome-wide cytosine methylation profiling with simultaneous copy number analysis and optimization for limited cell numbers.&rdquo;&nbsp;<strong>Nucleic Acids Res.</strong>&nbsp;2009 Jul;37(12):3829-39.&nbsp;&nbsp; PMID: 19386619</li>
<li>Sohal D, Yeatts A, Ye K, Pellagatti A, Zhou L, Pahanish P, Mo Y, Bhagat T, Mariadason J, Boultwood J, Melnick A, Greally JM,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;Meta-analysis of microarray studies reveals a novel hematopoietic progenitor cell signature and demonstrates feasibility of inter-platform data integration.&rdquo;&nbsp;<strong>PLOS One</strong>&nbsp;2008 Aug 13;3(8):e2965&nbsp;&nbsp;&nbsp; PMID: 18698424</li>
<li>Zhou L, Nguyen AN, Sohal D, Ma JY, Pahanish P, Gundabolu K, Hayman J, Chubak A,&nbsp;&nbsp; Mo Y, Bhagat T, Das B, Haghnazari E, Navas T, Parmar S, Kambhampati S, Pellagati A,&nbsp; Braunchweig I, Zhang YE, Wickrema A, Boultwood J, Platanias LC, Higgins LS, List A, Bitzer M,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;Inhibition of Transforming Growth Factor beta receptor I kinase can stimulate hematopoiesis in Myelodysplasia.&rdquo;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>Blood</strong>&nbsp;2008 Oct 15;112(8):3434-43&nbsp; PMID: 18474728</li>
<li>Navas T, Zhou L, Estes M, Haghnazari E, Nguyen A, Mo Y, Pahanish P, Mohindru M, Cao T, Higgins L, Platanias LC, List A,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;Inhibition of p38a MAPK disrupts the pathological loop of proinflammatory factor production in the Myelodysplastic Syndrome bone marrow microenvironment.&rdquo; &nbsp;<strong>Leukemia and Lymphoma</strong>&nbsp;2008 Oct;49(10):1963-75</li>
<li>Zhou L, Opalinska J,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;p38 MAP kinase regulates stem cell apoptosis in human hematopoietic failure.&rdquo;&nbsp;<strong>Cell Cycle&nbsp;</strong>2007<strong>,</strong>&nbsp;1;6(5):534</li>
<li>Navas T, Mohindru M, Estes M, Ma JY, Sokol L, Pahanish P,&nbsp;Parmar S, Haghnazari E, Zhou L, Collins RC, Kerr I, Nguyen A, Xu Y, Platanias LC, List AA, Higgins LS,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors.&rdquo;&nbsp;<strong>Blood&nbsp;</strong>2006, 15;108(13):4170-7</li>
<li><strong>Verma A,</strong>&nbsp;and List A, &ldquo;Cytokine Targets in Myelodysplastic syndromes.&rdquo;&nbsp;<strong>Current Hematology Reports</strong>&nbsp;2005 Nov;4(6):429-35</li>
<li>Deonarain R,&nbsp;<strong>Verma A,</strong>&nbsp;Porter AC, Gewert DR, Platanias LC, Fish EN, &ldquo;Critical roles for IFN-beta in lymphoid development, myelopoiesis, and tumor development: links to tumor necrosis factor alpha.&rdquo;&nbsp;<strong>Proc Natl Acad Sci USA.</strong>&nbsp;2003 Nov 11;100(23):13453-8</li>
<li><strong>Verma A,</strong>&nbsp;Devine S, Morrow M, Chen YH, Mihalov M, Peace D, Stock W, Pursell K, Wickrema A, Yassine M, Jessop E, Van Besien K, &ldquo;Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir.&rdquo;&nbsp;&nbsp;<strong>Bone Marrow Transplant.</strong>&nbsp;2003 May;31(9):813-6.</li>
<li><strong>Verma A.,</strong>&nbsp;Mohindru M., Deb D., Sassano A., Kambhampati S., Minucci S., Ravandi F., Kovakanalu D, Platanias L., &ldquo;Activation of the Rac1 and p38 MAP kinase pathway in response to Arsenic trioxide.&rdquo;&nbsp;&nbsp;<strong>Journal of Biological Chemistry</strong>&nbsp;22;277(47):44988-95</li>
<li><strong>Verma A,</strong>&nbsp;Sassano A, Deb D, Wickrema, A., VanBesien K., and Platanias L., &ldquo;Blockade of p38 MAP kinase reverses cytokine mediated inhibition in aplastic anemia.&rdquo;&nbsp;<strong>Journal of Immunology</strong>&nbsp;2002, 168 (12) (Cutting edge section)</li>
<li><strong>Verma A,</strong>&nbsp;Deb D.K., Sassano A., Uddine S., Wickrema A., Varga and Platanias LC, &ldquo;Activation of the p38 mitogen activated protein kinase mediates suppressive effects of Type I interferons and transforming growth factor-b on normal hematopoiesis.&rdquo;&nbsp;<strong>Journal of Biological Chemistry</strong>&nbsp;2002, 277(10):7726-35</li>
<li>Devine S, Hoffman R,&nbsp;<strong>Verma A,</strong>&nbsp;Shah R, Bradlow B, Stock W and Van Besien K, &ldquo;Allogeneic blood cell transplantation following reduced intensity conditioning is effective therapy for older patients with myelofibrosis.&rdquo;<strong>&nbsp;Blood&nbsp;</strong>&nbsp;2002, 99(6):2255-8</li>
</ol>
<p><strong>Review articles</strong></p>
<ol start="1" type="1">
<li>Li W, Morrone K, Kambhampati S, Will B, Steidl U,&nbsp;<strong>Verma A,&nbsp;</strong>&ldquo;Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.&rdquo;&nbsp;<strong>Leukemia,&nbsp;</strong>2015 (In Press)</li>
<li>Shenoy N, Vallumsetla N, Zou Y, Galeas JN, Shrivastava M, Hu C, Susztak K,&nbsp;<strong>Verma A.,&nbsp;</strong>"Role of DNA methylation in renal cell carcinoma."&nbsp;<strong>J Hematol Oncol.</strong>&nbsp;2015 Jul 22;8(1):88. PMID: 26198328</li>
<li><strong>Verma A,</strong>&nbsp;Steidl U., &ldquo;A synthetic lethal approach targeting mutant isocitrate dehydrogenase in acute myeloid leukemia.&rdquo;&nbsp;<br />
<strong>Nat Med.</strong>&nbsp;2015;21:113-4.&nbsp; PMID: 25654599</li>
<li>Ga&ntilde;&aacute;n-G&oacute;mez I, Wei Y, Starczynowski DT, Colla S, Yang H, Cabrero-Calvo M, Bohannan ZS,&nbsp;<strong>Verma A,</strong>&nbsp;Steidl U, Garcia-Manero G, "Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes."&nbsp;<strong>Leukemia.</strong>&nbsp;2015 Mar 12. PMID: 25761935</li>
<li>Shenoy N, Vallumsetla N,&nbsp; Rachmilewitz E,&nbsp;<strong>Verma A,</strong>&nbsp;Ginzburg Y., "Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome."&nbsp;<strong>Blood,</strong>&nbsp;2014 Aug 7;124(6):873-81. PMID: 24923296</li>
<li>Das BC, Thapa P, Karki R, Das S, Mahapatra S, Liu TC, Torregroza I, Wallace DP, Kambhampati S, Van Veldhuizen P,&nbsp;<strong>Verma A,</strong>&nbsp;Ray SK,&nbsp;&nbsp;&nbsp; Evans T.,&nbsp; "Retinoic acid signaling pathways in development and diseases."<br />
<strong>Bioorg Med Chem.</strong>&nbsp;2014 Jan 15;22(2):673-83. PMID: 24393720</li>
<li>Elias HK, Schinke C, Bhattacharyya S, Will B*,&nbsp;<strong>Verma A*,&nbsp;</strong>&nbsp;Steidl U* *CoCorresponding,&nbsp;&nbsp;&nbsp; &ldquo;Stem cell origin of myelodysplastic syndromes.&rdquo;&nbsp;<strong>Oncogene</strong>&nbsp;2013 Dec 16. PMID: 24336326</li>
<li>Pathak S, Roth M,&nbsp;<strong>Verma A*,</strong>&nbsp;Steidl U*.&nbsp; *CoCorresponding,&nbsp;&nbsp;&nbsp; &ldquo;Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders.&rdquo;<br />
<strong>Expert Opin Drug Metab Toxicol.</strong>&nbsp;2013 Dec;9(12):1667-75. PMID: 24215532</li>
<li>Feld J, Barta SK, Schinke C, Braunschweig I, Zhou Y,&nbsp;<strong>Verma AK,&nbsp;&nbsp;</strong>&ldquo;Linked-in: design and efficacy of antibody drug conjugates in oncology.&rdquo;&nbsp;<strong>Oncotarget</strong>&nbsp;2013 Mar;4(3):397-412. PMID: 23651630</li>
<li>Khan H, Vale C, Bhagat T,&nbsp;<strong>Verma A.,&nbsp;&nbsp;&nbsp;</strong>&ldquo;Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes.&rdquo;<br />
<strong>Semin Hematol.</strong>&nbsp;2013 Jan;50(1):16-37. PMID: 23507481</li>
<li>Elias H,&nbsp;<strong>Verma A,&nbsp;&nbsp;</strong>&ldquo;Activation of hypoxia signaling is marker of poor prognosis in myelodysplasia.&rdquo;<br />
<strong>Leuk Lymphoma.</strong>&nbsp;2012 Dec;53(12):2337-8. PMID: 22897726</li>
<li>Shenoy N, Kessel R, Bhagat TD, Bhattacharyya S, Yu Y, McMahon C,&nbsp;<strong>Verma A.,&nbsp;&nbsp;</strong>&ldquo;Alterations in the ribosomal machinery in cancer and hematologic disorders.&rdquo;&nbsp;<strong>J Hematol Oncol.</strong>&nbsp;2012 Jun 18;5:32. PMID: 22709827</li>
<li>Agarwal A, Polineni R, Hussein Z, Vigoda I, Bhagat TD, Bhattacharyya S, Maitra A,&nbsp;<strong>Verma A.,&nbsp;&nbsp;</strong>&ldquo;Role of epigenetic alterations in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma.&rdquo;&nbsp;<strong>Int J Clin Exp Pathol.</strong>&nbsp;2012;5(5):382-96. PMID: 22808291</li>
<li>Sharma A,&nbsp; Heuck C, Fazzari M, Mehta J, Singhal S, Greally JM,&nbsp;<strong>Verma A,&nbsp;&nbsp;</strong>&ldquo;DNA methylation alterations seen in myeloma as a model of epigenetic changes in cancer.&rdquo;&nbsp;<strong>WIREs Systems Biology and Medicine</strong>&nbsp;2010 Nov-Dec;2(6):654-69. PMID: 20890963</li>
<li>Schinke C, Mo Y, Yu Y, Amiri K, Sosman J, Greally JM,&nbsp;<strong>Verma A,&nbsp; &ldquo;</strong>Aberrant DNA methylation in malignant melanoma.&rdquo;&nbsp;<strong>Melanoma Research</strong>&nbsp;2010, Aug; 20(4):253-65 PMID: 20418788</li>
<li>Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B,&nbsp;<strong>Verma A.,&nbsp;</strong>&ldquo;Mechanism of action of lenalidomide in hematological malignancies.&rdquo;<br />
<strong>J Hematol Oncol.</strong>&nbsp;2009 Aug 12;2:36</li>
<li>Opalinska J, Zhou L,&nbsp;<strong>Verma A.,&nbsp;</strong>&ldquo;A new PML-RARs fusion transcript hints at the important role of PML dysregulation in the pathogenesis of APL.&rdquo;&nbsp;<strong>Leukemia Research (Commentary)</strong>&nbsp;2007, 48(3):443</li>
<li>Isufi I, Seetharam M, Sohal D, Zhou L, Opalinska J, Pahanish P,&nbsp;<strong>Verma A., &ldquo;</strong>Transforming Growth Factor-beta Signaling in Normal and Malignant Hematopoiesis.&rdquo;&nbsp;<strong>Journal of Interferon and Cytokine Research</strong>&nbsp;2007, 27(7):543</li>
<li>Mohindru M,&nbsp;<strong>Verma A,&nbsp;&nbsp;</strong>&ldquo;Engineered antibodies act as targeted therapies in cancer treatment.&rdquo;&nbsp;<strong>Indian Journal of Pediatrics,</strong>&nbsp;2005 Nov;72(11):943-7</li>
<li>Sassano A,&nbsp;<strong>Verma A,</strong>&nbsp;Platanias LC, "Mitogen-activated protein kinase pathways in interferon signaling."&nbsp;<strong>Methods Molecular Medicine,</strong>&nbsp;2005;116:135-50.</li>
<li>Mohindru M,&nbsp;<strong>Verma A,&nbsp;</strong>"Kinase inhibitors translate lab discoveries into exciting new cures for cancers."&nbsp;<strong>Indian Journal of Pediatrics,</strong>&nbsp;2004 Aug;71(8):713-8.</li>
<li><strong>Verma A,</strong>&nbsp;Kambhampati S, Parmar S, Platanias LC,&nbsp; &ldquo;Jak family of kinases in cancer.&rdquo;&nbsp;<strong>Cancer Metastasis Rev.</strong>&nbsp;2003 Dec;22(4):423-34.(rev)</li>
<li><strong>Verma A,</strong>&nbsp;and Platanias LC, &ldquo;Signaling via the interferon-a receptor in chronic myelogenous leukemia cells.&rdquo;&nbsp;<strong>Leukemia and Lymphoma&nbsp;</strong>&nbsp;2002, 44:703-709</li>
<li><strong>Verma A,</strong>&nbsp;and Stock W, &ldquo;Management of adult lymphoblastic leukemia: moving toward a risk-adapted approach.&rdquo;&nbsp;<strong>Current Opinion in Oncology,</strong>&nbsp;2001, 13:14-20</li>
<li><strong>Verma A,</strong>&nbsp;and Gupta YK,&nbsp; &ldquo;The search for a super oral rehydration solution (0RS).&rdquo;&nbsp;<strong>Drugs: News and Views,</strong>&nbsp;1995, 3(2):129-132.&nbsp;</li>
</ol>

EMR ID

4772

Biography

<p>Amit K. Verma, MD, is Interim Chair, Department of Oncology, Associate Director of Translational Science, Montefiore Einstein Comprehensive Cancer Center, Professor, Medical Oncology and Professor, Developmental & Molecular Biology, Albert Einstein College of Medicine.</p><p>Dr. Verma earned his Doctor of Medicine at the All India Institute of Medical Sciences in 1995 and finished his training in internal medicine, hematology oncology and stem cell transplantation at the University of Illinois and Northwestern University in 2003.</p><p>Dr. Verma conducts clinical studies for patients with MDS and leukemia and offers a variety of clinical trials for these patients. He conducts laboratory research aimed at discovering new treatments for myelodysplastic syndromes (MDS) and leukemias, and his research has shown that the TGF-beta superfamily/smad, IRAK and MAP kinase pathways are overactivated in MDS. His work has led to clinical trials with Luspatercept, Galunisertib, CA4948, ARRY-614 and various other promising agents in MDS. DR. Verma&rsquo;s research has shown that MDS and leukemias are caused by aberrant leukemic stem cells and has identified novel targets against MDS/AML stem cells that are being tested in various studies.</p><p>Dr. Verma is a scholar of the Leukemia and Lymphoma society, elected member of American society of clinical investigation and his research is funded by the NIH, Department of Defense, American Cancer Society, Edward P. Evans Foundation and various other private foundations.</p>

Is Open Scheduling

Off

Rafi Kabarriti

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/05986ec0-4373-11ee-9d6f-374ce67539f5.jpg

First Name

Rafi

Last Name

Kabarriti

NPI

1811200256

Faculty ID

15596

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Rafi Kabarriti, MD, is a cum laude graduate of Columbia University with a bachelor&rsquo;s degree in biochemistry and economics.&nbsp;&nbsp;He earned his medical degree at Albert Einstein College of Medicine and completed an internship in internal medicine at Mount Sinai St. Luke's and Mount Sinai West Hospital and a residency in radiation oncology at Montefiore Medical Center, where he was chief resident in the Department of Radiation Oncology.&nbsp;&nbsp;Dr. Kabarriti is the recipient of the prestigious American Society of Clinical Oncology and Conquer Cancer Foundation Young Investigator Award, Empire Clinical Research Investigator Program Fellowship and AIDS Malignancy Consortium fellowship Award.&nbsp;&nbsp;He is also funded by the NIH K12 Paul Calabresi Career Development Award for Clinical Oncology.&nbsp;&nbsp;His research has been selected for oral presentations at national and international meetings including the annual meetings of the American Society for Radiation Oncology, European Society for Radiotherapy, and the European ORL-HNS Congress. Dr. Kabarriti is author and co-author of over 40 articles published in peer-reviewed journals including the Journal of Clinical Oncology, International Journal of Radiation Oncology, Biology, and Physics, Oral Oncology and Head and Neck.&nbsp;His research focus is on optimizing radiation therapy for head and neck and gastrointestinal cancers and combining radiation therapy with novel therapeutics and immunotherapy to improve outcomes for these patients.&nbsp;&nbsp;He is the principal investigator of multiple clinical trials including investigator-initiated clinical trials as well as the local PI on cooperative and international studies.&nbsp;&nbsp;&nbsp;</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Treatment of head and neck, gastrointestinal and other cancer types, and use of advanced technologies in radiation oncology including image guidance, stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS).

Research Focus

Novel therapeutics for the monitoring and management of radiation-induced toxicities using the liver as a model; Integration of radiation therapy with immunotherapy agents to produce a strong anti-tumor systemic immune response.

Elsevier Profile

Selected Publications

<h3>Selected Publications:</h3>
<p>1. &nbsp;<strong>Kabarriti, R</strong>. Ohri, N. Hannan, R. Tishbi, N.&nbsp;Baliga, S. McGovern, KP. Mourad, WF.&nbsp;Ghavamian, R. Kalnicki, S. Guha, C. Garg, MK. PSA Decline During Salvage Radiation Therapy Following Prostatectomy Is Associated With Reduced Biochemical Failure.&nbsp;&nbsp;Practical Radiation Oncology, 2014 Feb 21. &nbsp;</p>
<p>2.&nbsp;&nbsp;<strong>Kabarriti, R</strong>. Guha, C. Hedgehog Signaling and Radiation Induced Liver Injury: A Delicate Balance.&nbsp;&nbsp;Hepatology International, 2014 Jul;8(3):316-20.</p>
<p>3.&nbsp;&nbsp;<strong>Kabarriti R</strong>, Mark D, Fox J, Kalnicki S, Garg MK.&nbsp;Proton therapy for the treatment of pediatric head and neck cancers: A review. Int J Pediatr Otorhinolaryngol. 2016 Jan;79(12)</p>
<p>4. &nbsp;<strong>Kabarriti R</strong>, Quinn TJ, Ewart MR, Mehta KJ, Lomita C, Geller DS, Kalnicki S, Fox JL. Neoadjuvant radiation therapy for the management of myoepithelial carcinoma of the upper extremity. Int J Cancer. 2018 Feb 15;142(4), PMCID: PMC6200873</p>
<p>5.&nbsp;&nbsp;<strong>Kabarriti R</strong>, Bontempo A, Romano M, McGovern KP, Asaro A, Viswanathan S, Kalnicki S, Garg MK. The Impact of Dietary Regimen Compliance on Outcomes for HNSCC Patients Treated with Radiation Therapy. Supportive Care in Cancer, 2018 Sep;26(9):3307-3313; PMID: 29671062</p>
<p>6. &nbsp;Ohri N,&nbsp;<strong>Kabarriti R</strong>, Kaubisch A, Guha C. RFA versus SBRT for HCC: Caution when Interpreting Observational Data; Journal of Clinical Oncology, 2018 Aug 20;36(24):2558; PMID: 29945527</p>
<p>7. &nbsp;Baliga S*,&nbsp;<strong>Kabarriti R*</strong>, Jiang J, Mehta V, Guha C, Kalnicki S, Smith RV, Garg, MK. Utilization of Transoral Robotic Surgery (TORS) in Patients with Oropharyngeal Squamous Cell Carcinoma and its impact on Survival and use of Chemotherapy.&nbsp;&nbsp;Oral Oncology, 2018 Nov;86:75-80; PMID: 30409323&nbsp;&nbsp;&nbsp;*co-first author</p>
<p>8. &nbsp;Brodin NP,&nbsp;<strong>Kabarriti R</strong>, Pankuch M, Schechter CB, Gondi V, Kalnicki S, Guha C, Garg MK, Tom&eacute; WA.&nbsp;&nbsp;A Quantitative Clinical Decision-support Strategy Identifying Which Oropharyngeal Head and Neck Cancer Patients may Benefit the Most from Proton Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018 Nov 26.&nbsp;&nbsp;PMID: 30496877</p>
<p>9. &nbsp;Barahman M, Asp P, Roy-Chowdhury N, Kinkhabwala M, Roy-Chowdhury J,&nbsp;<strong>Kabarriti R</strong>, Guha C.&nbsp;&nbsp;Hepatocyte Transplantation: Quo Vadis? Int J Radiat Oncol Biol Phys. 2018 Nov 29.&nbsp;&nbsp;PMID: 30503786</p>
<p>10.&nbsp;&nbsp;<strong>Kabarriti R</strong>, Brodin NP, Lundgren G, Ohri N, Tom&eacute;, WA, Kalnicki S, Garg MK. Early Response Assessment on Mid-Treatment CT Predicts Loco-Regional Recurrence in Oropharyngeal Cancer Patients Treated with Definitive Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1036-1045; PMID: 29779936</p>
<p>11.&nbsp;<strong>Kabarriti R</strong>, Baliga S, Ohri N, Guha C, Kalnicki S, Garg, MK. Radiotherapy for Patients With Newly Diagnosed Metastatic Head and Neck Squamous Cell Carcinoma.&nbsp;&nbsp;Head and Neck, 2018 Dec 16.&nbsp;&nbsp;PMID: 30556318</p>
<p>12. &nbsp;Barahman M, Zhang W, Yaffe Harris H, Aiyer A,&nbsp;<strong>Kabarriti R</strong>, Kinkhabwala M, Roy-Chowdhury N, Beck AP, Scanlan TS, Roy-Chowdhury J, Asp P, Guha C. Radiation-primed hepatocyte transplantation in murine monogeneic dyslipidemia normalizes cholesterol and prevents atherosclerosis.&nbsp;&nbsp;J Hepatol. 2019 Jan 14.&nbsp;&nbsp;PMID: 30654068</p>
<p>13.&nbsp;&nbsp;<strong>Kabarriti R</strong>, Brodin NP, Ahmed S, Vogelius I, Guha C, Kalnicki S, Tom&eacute; WA, Garg MK.&nbsp;&nbsp;Origin of Locoregional Recurrences After Definitive Intensity-modulated Radiation Therapy (IMRT) for Laryngeal Cancer Determined Based on Follow-up PET/CT Imaging.&nbsp;&nbsp;Cureus. 2019 Jan 8;11(1):e3856; PMID: 30899607</p>
<p>14. &nbsp;Jiang JM, Ohri N, Tang J, Moadel R, Cynamon J, Kaubisch A, Kinkhabwala M, Garg MK, Guha C,&nbsp;<strong>Kabarriti R</strong>.&nbsp;&nbsp;Centers with More Therapeutic Modalities are Associated with Improved Outcomes for Patients with Hepatocellular Carcinoma.&nbsp;&nbsp;Journal of Gastrointestinal Oncology, 2019 Jun;10(3):546-553. PMID: 31183206</p>
<p>15.&nbsp;&nbsp;<strong>Kabarriti R</strong>, Brodin NP, Ohri N, Narang R, Huang R, Chuy JW, Rajdev LN, Kalnicki S, Guha C, Garg MK.&nbsp;&nbsp;Human Papillomavirus, Radiation Dose and Survival of Patients with Anal Cancer. Acta Oncolgica, 2019 Jul 8:1-7, PMID: 31282249</p>
<p>16. &nbsp;Zhu S, Brodin NP, English K, Ohri N, Chuy JW, Rajdev LN, Narang R, Kalnicki S, Guha C, Garg MK,&nbsp;<strong>Kabarriti R. &nbsp;</strong>Comparing Outcomes Following Total Neoadjuvant Therapy and Following Neoadjuvant Chemoradiation Therapy in Patients with Locally Advanced Rectal Cancer.&nbsp;EClinicalMedicine, in Press</p>

EMR ID

54490

Biography

<p class="MsoNormal">Rafi Kabarriti, MD, is a cum laude graduate of Columbia University with a bachelor&rsquo;s degree in biochemistry and economics.</p><p class="MsoNormal">Dr. Kabarriti earned his medical degree at Albert Einstein College of Medicine and completed a residency in internal medicine at St. Luke&rsquo;s-Roosevelt Hospital Center and a residency in radiation oncology at Montefiore Medical Center, where he was chief resident in the Department of Radiation Oncology.</p><p class="MsoNormal">Dr.Kabarriti is the recipient of the 2014 Young Investigator Award given by the Conquer Cancer Foundation and the American Society of Clinical Oncology. In addition, his abstracts have been selected for oral presentations at national and international meetings including the annual meetings of the American Society for Radiation Oncology. Dr. Kabarriti is author and co-author of articles published in peer-reviewed journals including <i>the International Journal of Radiation Oncology</i><i>&bull;Biology</i><i>&bull;Physics</i>, <i>Hepatology International</i>, and <i>PLoS One</i>.</p>

Is Open Scheduling

Off

Kira Gritsman

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/6b993220-5d55-11ef-92db-0be6da54f487.jpg

First Name

Kira

Last Name

Gritsman

NPI

1174598148

Faculty ID

14128

CMO Specialties

Clinical Terms

Employment Status

part-time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><strong>The Roles of Signaling Pathways in Adult Blood Development and Leukemia</strong></p>
<p><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">The Gritsman lab studies the signal transduction pathways that affect the early fate decisions of adult hematopoietic stem cells (HSCs) as they progress from an undifferentiated multipotent state to the generation of differentiated blood cells.&nbsp; When these early fate decisions go awry, this can lead to the formation of leukemia-initiating cells. We are interested in</span><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">&nbsp;how signaling pathways affect the self-renewal and differentiation of HSCs and malignant or pre-malignant stem cells in myeloid malignancies, such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPN).</span></p>
<p><strong>Roles of the PI3 kinase isoforms in adult blood development</strong></p>
<p>PI3 kinase (PI3K) is a lipid kinase that is important for the regulation of metabolism, the cell cycle, apoptosis, and protein synthesis. &nbsp;In hematopoietic cells, there are four isoforms of the catalytic subunit of PI3K, each encoded by a separate gene. &nbsp;Emerging evidence suggests that these isoforms have unique functions in normal and cancer cells, but may substitute for each other in some contexts.&nbsp; We have generated a series of mouse knockout models that allow us to study the roles of each of these isoforms individually in adult hematopoiesis.&nbsp; For example, we have found that the p110alpha isoform is most important for red cell development, but is not required in normal blood stem cells. We have now also generated compound knockout mice to determine the redundant roles of the PI3K isoforms in blood development. &nbsp;We recently reported that PI3K isoforms play important redundant roles during the hematopoietic stress response, such as after chemotherapy. However, deletion of all 3 Class IA PI3K isoforms leads to a phenotype with impaired HSC differentiation, resembling myelodysplastic syndrome (MDS). We are studying how deletion of PI3K will impact normal HSC function, including self-renewal, proliferation, and differentiation along different blood lineages by affecting processes such as autophagy and epigenetic regulation in HSCs.</p>
<p><strong>Roles of the PI3 kinase isoforms in leukemia</strong></p>
<p>Acute myeloid leukemia (AML) is a genetically diverse disease, but activation of the PI3K pathway has been reported in up to 80% of cases.&nbsp; A subset of AML cell lines and AML patient samples respond to PI3K pathway inhibitors, but it is unclear how patients should be selected for potential response to these inhibitors. &nbsp;We found that RAS-mutated myeloid leukemias are particularly dependent on the p110alpha isoform of PI3K, and that pharmacologic inhibition of p110alpha can be used to treat both RAS-mutated cell lines and RAS-mutated leukemia in mice. Furthermore, we use cell lines, patient samples, and mouse models of leukemia to investigate the mechanisms of resistance to PI3K inhibition, with the goal of identifying new drug targets and designing new combination treatments for leukemia that incorporate PI3K inhibitors.</p>
<p><strong>RON Kinase in Myeloproliferative Neoplasms</strong></p>
<p>The myeloproliferative neoplasms (MPNs) are a group of diseases that are caused by kinase mutations in HSCs, which lead to uncontrolled proliferation of myeloid cells. The Philadelphia chromosome-negative MPNs are characterized by mutations in the JAK/STAT signaling pathway, and respond to JAK inhibitors, but resistance often develops. We recently discovered that the receptor Tyrosine kinase RON can physically interact with JAK2 in MPN cells, leading to potentiation of JAK/STAT signaling in resistant cells. Furthermore, we found that pharmacologic or genetic inactivation of RON can inhibit proliferation of MPN cells and re-sensitize resistant cells to JAK inhibitors.</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: 'Times New Roman', serif;"><strong><span style="font-size: 10.5pt; font-family: Verdana, sans-serif; color: #201f1e;">Member of the Cancer Dormancy and Tumor Microenvironment Institute&nbsp;</span></strong></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: 'Times New Roman', serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: 'Times New Roman', serif;"><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">&nbsp;</span><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">The Gritsman lab&rsquo;s research interests include the contributions of signaling pathways to leukemic and pre-leukemic stem cell dormancy in minimal residual disease, which includes mechanisms of immune evasion. Furthermore, the Gritsman lab is interested in the roles of inflammatory signaling pathways and of the local microenvironment in bone marrow fibrosis, and in the evolution of myeloid neoplasms from the pre-malignant to malignant state. Our major goals are to identify opportunities for therapeutic targeting to prevent the transition from the pre-leukemic state to leukemia, or to eliminate minimal residual disease to prevent relapse.</span></p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><a name="_GoBack"></a><span style="font-size: 11pt; font-family: Arial, sans-serif;">Ames, K.,&nbsp;^&nbsp;Kaur,^&nbsp;I., Shi, Y., Tong, M., Sinclair, T., Hemmati, S., Glushakow-Smith, S.G., Tein,&nbsp;&nbsp;E., Gurska, L., Steidl, U., Dubin, R., Shan, J., Montagna, C., Pradhan, K., Verma, A., and&nbsp;<strong><u>Gritsman, K.</u></strong>, Deletion of PI3-Kinase Promotes Myelodysplasia Through Dysregulation of Autophagy in Hematopoietic Stem Cells,&nbsp;<strong><em>Science Advances</em></strong><em>&nbsp;2023.&nbsp;</em>doi:&nbsp;<a href="https://nam04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fdoi.o…; target="_blank" rel="noopener"><span style="color: black; text-decoration: none;">10.1126/sciadv.ade8222</span></a><u>,&nbsp;</u>PMID:&nbsp;36812307</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><em><span style="font-size: 11pt; font-family: Arial, sans-serif;">&nbsp;</span></em></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Folgado Marco, V., Ames, K., Chuen, J.,&nbsp;<strong><u>Gritsman, K.</u></strong>&nbsp;&amp; Baker, N.,&nbsp;Haploinsufficiency of the essential gene&nbsp;<em>RpS12</em>&nbsp;causes defects in erythropoiesis and hematopoietic stem cell maintenance,&nbsp;<em>&nbsp;<strong>eLife</strong>&nbsp;</em>2023&nbsp;Jun 5;12:e69322. doi: 10.7554/eLife.69322.&nbsp;PMID:&nbsp;37272618</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">&nbsp;</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Gurska, L.M., Okabe, R., Schurer, A., Tong, M.M., Soto, M., Choi, D., Ames, K., Glushakow-Smith, S., Montoya, A., Tein, E., Miles, L.A., Cheng, H., Hankey-Giblin, P., Levine, R.L., Goel, S., Halmos, B., and&nbsp;<strong><u>Gritsman, K.</u></strong>&nbsp;Crizotinib has Preclinical Efficacy in Philadelphia-negative Myeloproliferative Neoplasms,&nbsp;<strong><em>Clinical Cancer Research</em></strong>&nbsp;2022&nbsp;Dec 20:CCR-22-1763. doi: 10.1158/1078-0432.CCR-22-1763. PMID:&nbsp;36537918</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">&nbsp;</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Gurska, L., Ames, K., and&nbsp;<strong><u>Gritsman, K</u></strong>, Signaling Pathways in Leukemic Stem Cells,&nbsp;</span><span style="font-size: 11pt; font-family: Arial, sans-serif; color: #333333; letter-spacing: 0.2pt; background-color: #fcfcfc;">In: Zhang H., Li S. (eds) Leukemia Stem Cells in Hematologic Malignancies.&nbsp;<strong>Advances in Experimental Medicine and Biology</strong>, vol 1143. Springer, Singapore</span><span style="font-size: 11pt; font-family: Arial, sans-serif;">, July 24, 2019, doi:&nbsp;<a href="https://doi.org/10.1007/978-981-13-7342-8_1"><span style="color: black; letter-spacing: 0.2pt; background-color: #fcfcfc; text-decoration: none;">https://doi.org/10.1007/978-981-13-7342-8_1</span></a><span style="letter-spacing: 0.2pt; background-color: #fcfcfc;">;&nbsp;</span>PMID:&nbsp;31338813, PMCID:&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7249489/&quot; target="_blank" rel="noopener"><span style="color: black; text-decoration: none;">PMC7249489</span></a></span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Hemmati, S., Sinclair, T., Tong, M., Bartholdy, B., Okabe, R.O., Ames, K., Ostrodka, L., Haque, T., Kaur, I., Mills, T. S., Agarwal, A., Pietras, E.M., Zhao, J.J., Roberts, T.M., and&nbsp;<strong><u>Gritsman, K.</u></strong>, PI3 kinase alpha and delta promote hematopoietic stem cell activation,&nbsp;<strong><em>JCI Insight&nbsp;</em></strong>2019&nbsp;doi.org/10.1172/jci.insight.125832</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Mitchell, K., Barreyro, L., Todorova, T., Taylor, S., Antony-Debre, I., Narayanagari, S., Carvajal, L., Leite, J., Piperdi, Z., Pendurti, G., Mantzaris, I., Paietta, E., Verma, A.,&nbsp;<strong><u>Gritsman, K.,&nbsp;</u></strong>and Steidl, U. IL1RAP potentiates multiple oncogenic signaling pathways in AML,&nbsp;<strong><em>Journal of&nbsp;Experimental Medicine</em></strong><em>.&nbsp;</em>2018 May 17. doi: 10.1084/jem.20180147,&nbsp;PMID: 29773641</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Hemmati, S., Haque, T., and&nbsp;<strong><u>Gritsman, K</u>,&nbsp;</strong>Inflammatory Signaling Pathways in Pre-leukemic and Leukemic Stem Cells,&nbsp;<strong><em>Frontiers in Oncology</em></strong><em>&nbsp;</em>2017 Nov 13;7:265. doi: 10.3389/fonc.2017.00265</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Bhagat, T.D., Chen, S., Bartenstein, M., Barlowe, A.T., Von Ahrens, D., Choudhary, G.S., Tivnan, P., Amin, E., Marcondes, M., Sanders, M.A., Hoogenboezem, R.M., Kambhampati, S., Ramanchandra, N., Mantzaris, I., Sukrithan, V., Laurence, R., Lopez, R. Bhagat, P., Giricz, O., Sohal, D., Wickrema, A., Yeung, C.,&nbsp;<strong><u>Gritsman, K.,</u></strong>&nbsp;Aplan, P., Hochedlinger, K., Yu, Y., Pradhan, K., Zhang, J., Greally, J.M., Mukherjee, S., Pellagatti, A., Boultwood, J., Will, B., Steidl, U., Raaijmakers, M.H.G.P., Deeg, H.J., Kharas, M.G. and Verma, A. Epigenetically Aberrant Stroma in MDS Propagates Disease Via Wnt/b-Catenin Activation, 2017&nbsp;<strong><em>Cancer Research</em></strong>&nbsp;2017 Jul 6. pii: canres.0282.2017. doi: 10.1158/0008-5472</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Yuzugullu, H., Baitsch, L., Von, T., Steiner, A., Tong, H., Ni, J., Clayton, L., Bronson, R., Roberts, T.,&nbsp;<strong><u>Gritsman, K</u></strong><u>.</u>, and Zhao, J.J. A p110b-Rac signaling loop mediates Pten-loss-induced perturbation of hematopoiesis and leukemogenesis.&nbsp;<strong><em>Nature Communication</em></strong><em>s&nbsp;</em>October 7,2015, doi:10.1038/NCOMMS9501</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Yoda, A., Adelmant, G., Tamburini, J., Chapuy, B., Shindoh, N., Yoda, Y., Weigert, O., Kopp, N., Wu, S-C., Kim, S., Liu, H., Tivey, T., Christie, A.L.,&nbsp;<strong><u>Gritsman, K.</u></strong>,&nbsp; Gotlib, J., Deininger, M., Turley, S., Tyner, J., Marto, J., Weinstock, D.M., and Lane, A.A. Mutations in G-protein beta subunits promote transformation and kinase inhibitor resistance&nbsp;<strong><em>Nature Medicine</em></strong><em>&nbsp;</em>2015 (1):71-5.</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><strong><u><span style="font-size: 11pt; font-family: Arial, sans-serif;">Gritsman, K</span></u></strong><strong><span style="font-size: 11pt; font-family: Arial, sans-serif;">.</span></strong><span style="font-size: 11pt; font-family: Arial, sans-serif;">, Yuzugullu, H., Von, T., Yan, H., Clayton, L., Fritsch, C., Maira, S.-M., Hollingworth, G., Choi, C., Khandan, T., Paktinat, M., Okabe, R.O., Roberts, T.M., and Zhao, J.J. &nbsp;Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110alpha<strong>.&nbsp;<em>Journal of Clinical Investigation&nbsp;</em></strong>2014;124(4):1794&ndash;1809.&nbsp;http://www.jci.org/articles/view/69927</span></p&gt;
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Kharas, M.G. and&nbsp;<strong><u>Gritsman, K</u></strong>. Akt: A Double-Edged Sword for Hematopoietic Stem Cells.&nbsp;<strong><em>Cell Cycle</em>&nbsp;</strong>2010; Vol 9; Issue 7</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Kharas, M.G., Okabe, R., Ganis, J.J., Gozo,M., Khandan,T., Paktinat, M., Gilliland, D.G., and&nbsp;<strong><u>Gritsman, K</u>.</strong>&nbsp;Constitutively Active AKT Depletes Hematopoietic Stem Cells and Induces Leukemia in Mice.&nbsp;<strong><em>Blood&nbsp;</em></strong>2010; 115(7): 140615&nbsp;http://www.bloodjournal.org/content/115/7/1406</span></p&gt;
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">&nbsp;</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">&nbsp;</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-family: 'Times New Roman', serif;">&nbsp;</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>

EMR ID

73180

Is Open Scheduling

Off

William R. Bodner

https://assets.montefioreeinstein.org/profiles/images/physphoto/Bodner_William_MD_420x504.jpg

First Name

William

Last Name

Bodner

NPI

1588714752

Faculty ID

10771

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

4856

Is Open Scheduling

Off